10-Q 1 a07-23916_110q.htm 10-Q

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


 

FORM 10-Q

(Mark One)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended July 31, 2007

 

 

or

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from               to               

Commission file number:  001-12531

ISONICS CORPORATION

(Exact name of registrant as specified in its charter)

 

California

 

77-0338561

(State or other jurisdiction of

 

(IRS Employer

incorporation or organization)

 

Identification No.)

 

5906 McIntyre Street
Golden, Colorado 80403
(Address of principal executive offices with zip code)

(303) 279-7900
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former
fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  x    No  o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer o

Non-accelerated filer x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)  Yes  o    No  x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class

 

Outstanding at September 12, 2007

 

Common Stock – no par value

 

12,658,150 shares

 

 

 




Isonics Corporation and Subsidiaries

TABLE OF CONTENTS

Part I:

Financial Information

 

 

 

 

 

Item 1:

Financial Statements

 

 

 

 

 

 

 

Condensed Consolidated Balance Sheets as of July 31, 2007 and April 30, 2007

 

 

 

 

 

 

 

Condensed Consolidated Statements of Operations for the Three Months Ended July 31, 2007 and 2006

 

 

 

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended July 31, 2007 and 2006

 

 

 

 

 

 

 

Notes to Condensed Consolidated Financial Statements

 

 

 

 

 

 

Item 2:

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

 

 

 

 

 

Item 3:

Quantitative and Qualitative Disclosures About Market Risk

 

 

 

 

 

 

Item 4:

Controls and Procedures

 

 

 

 

 

Part II:

Other Information

 

 

 

 

 

Item 1:

Legal Proceedings

 

 

 

 

 

 

Item 1A:

Risk Factors

 

 

 

 

 

 

Item 2:

Unregistered Sales of Equity Securities and Use of Proceeds

 

 

 

 

 

 

Item 4:

Submission of Matters to a Vote of Security Holders

 

 

 

 

 

 

Item 5:

Other Information

 

 

 

 

 

 

Item 6:

Exhibits

 

 

 

 

 

Signatures

 

 

2




Part I:  Financial Information

Item 1: Financial Statements

Isonics Corporation and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share amounts)

ASSETS

 

 

 

(Unaudited)

 

 

 

 

 

July 31, 2007

 

April 30, 2007

 

CURRENT ASSETS:

 

 

 

 

 

Cash and cash equivalents

 

$

1,482

 

$

1,556

 

Accounts receivable (net of allowances of $148 and $146, respectively)

 

3,416

 

3,678

 

Inventories

 

1,363

 

1,259

 

Prepaid expenses and other current assets

 

1,216

 

1,388

 

Assets of discontinued operations

 

 

491

 

Total current assets

 

7,477

 

8,372

 

 

 

 

 

 

 

LONG-TERM ASSETS:

 

 

 

 

 

Property and equipment, net

 

5,966

 

5,666

 

Goodwill

 

3,631

 

3,631

 

Intangible assets, net

 

259

 

303

 

Equity in net assets of investee

 

340

 

382

 

Other assets

 

565

 

606

 

Total long-term assets

 

10,761

 

10,588

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

18,238

 

$

18,960

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

(Unaudited)

 

 

 

 

 

July 31, 2007

 

April 30, 2007

 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts payable

 

$

976

 

$

973

 

Accrued liabilities

 

2,608

 

2,522

 

Derivative liabilities

 

1,008

 

1,021

 

Current portion of obligations under capital lease

 

487

 

340

 

Current portion of notes payable

 

445

 

134

 

Current portion of convertible debentures, net of discount

 

 

 

Liabilities of discontinued operations

 

 

72

 

Total current liabilities

 

5,524

 

5,062

 

 

 

 

 

 

 

Obligations under capital lease, net of current portion

 

1,085

 

710

 

Notes payable, net of current portion

 

 

 

Other long-term liabilities

 

1,478

 

888

 

Convertible debentures, net of discount and current portion

 

9,374

 

8,634

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

17,461

 

15,294

 

 

 

 

 

 

 

Minority interest in consolidated subsidiary

 

11

 

111

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY:

 

 

 

 

 

Common stock - no par value; 175,000,000 shares authorized; shares issued and outstanding: July 31, 2007 – 12,658,150; April 30, 2007 – 12,639,400

 

64,348

 

64,319

 

Additional paid in capital

 

20,872

 

20,705

 

Accumulated deficit

 

(84,454

)

(81,469

)

Total stockholders’ equity

 

766

 

3,555

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$

18,238

 

$

18,960

 

 

See notes to condensed consolidated financial statements.

3




Isonics Corporation and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

(Unaudited)

 

 

Three Months Ended

 

 

 

July 31,

 

 

 

2007

 

2006

 

Revenues:

 

$

 

 

$

 

 

Products

 

871

 

1,598

 

Services

 

4,998

 

5,188

 

Total revenues

 

5,869

 

6,786

 

 

 

 

 

 

 

Cost of revenues:

 

 

 

 

 

Products

 

875

 

1,430

 

Services

 

4,123

 

4,137

 

Total cost of revenues

 

4,998

 

5,567

 

 

 

 

 

 

 

Gross margin

 

871

 

1,219

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

Selling, general and administrative

 

2,090

 

3,768

 

Research and development

 

1,017

 

1,404

 

Total operating expenses

 

3,107

 

5,172

 

 

 

 

 

 

 

Operating loss

 

(2,236

)

(3,953

)

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

Amortization of debt issuance costs

 

(41

)

(115

)

Interest and other income

 

97

 

40

 

Interest expense

 

(1,429

)

(650

)

Foreign exchange

 

 

 

Gain on extinguishment of debt

 

 

227

 

Gain on derivative instruments

 

13

 

2,131

 

Equity in net loss of investee

 

(42

)

(88

)

Total other income (expense), net

 

(1,402

)

1,545

 

Loss from continuing operations before income taxes and minority interest

 

(3,638

)

(2,408

)

Income tax expense

 

 

 

Minority interest in operations of consolidated subsidiary

 

100

 

 

Loss from continuing operations

 

(3,538

)

(2,408

)

Discontinued operations:

 

 

 

 

 

Gain on operations of discontinued operations, net of income taxes

 

37

 

36

 

Gain on disposal of discontinued operations, net of income taxes

 

516

 

 

Gain on discontinued operations, net of income taxes

 

553

 

36

 

NET LOSS

 

$

(2,985

)

$

(2,372

)

 

 

 

 

 

 

Net income (loss) per share – basic and diluted:

 

 

 

 

 

Continuing operations

 

$

(0.28

)

$

(0.21

)

Discontinued operations

 

$

0.04

 

$

0.00

 

Attributable to common stockholders

 

$

(0.24

)

$

(0.21

)

Weighted average common shares used in computing per share information

 

12,654

 

11,367

 

 

See notes to condensed consolidated financial statements.

4




Isonics Corporation and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except share amounts)

(Unaudited)

 

 

Three Months Ended July 31,

 

 

 

2007

 

2006

 

 

 

 

 

 

 

Net cash used in operating activities

 

$

(453

)

$

(3,442

)

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

Purchases of property and equipment

 

(96

)

(360

)

Equity investment in a business

 

 

(100

)

Proceeds from sale of discontinued operations, net of selling costs

 

805

 

 

Cash provided by (used in) investing activities

 

709

 

(460

)

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

Principal payments under capital lease obligations

 

(106

)

(3

)

Principal payments on borrowings

 

(224

)

(4,549

)

Proceeds from issuance of common stock

 

 

15

 

Proceeds from the issuance of convertible debentures and related warrants, net of offering costs

 

 

12,270

 

Cash (used in) provided by financing activities

 

(330

)

7,733

 

 

 

 

 

 

 

NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS

 

(74

)

3,831

 

Cash and cash equivalents at beginning of period

 

1,556

 

1,586

 

Cash and cash equivalents at end of period

 

$

1,482

 

$

5,417

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information:

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

Interest

 

$

71

 

$

70

 

Income taxes

 

$

 

$

 

 

 

 

 

 

 

Supplemental disclosure of noncash investing and financing activities:

 

 

 

 

 

Capital lease obligation for property and equipment

 

$

628

 

$

 

Accruals for property and equipment

 

$

 

$

245

 

Capitalized debt issuance costs associated with issuance of common stock in a financing transaction

 

$

 

$

601

 

Payment in common stock of principal due on convertible debentures

 

$

 

$

3,943

 

 

See notes to condensed consolidated financial statements.

5




Isonics Corporation and Subsidiaries

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - BASIS OF PRESENTATION

The accompanying condensed consolidated balance sheet as of April 30, 2007, has been derived from audited financial statements.  The accompanying unaudited interim condensed consolidated financial statements of Isonics Corporation and Subsidiaries have been prepared on the same basis as the annual audited financial statements and in accordance with accounting principles generally accepted in the United States (“US GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements.  In the opinion of management, such unaudited information includes all adjustments (consisting only of normal recurring accruals) necessary for a fair presentation of this interim information.  Operating results and cash flows for interim periods are not necessarily indicative of results that can be expected for the entire year.  The information included in this report should be read in conjunction with our audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended April 30, 2007.

During the three months ended January 31, 2007, we reclassified the operations of our life sciences business as discontinued operations in accordance with SFAS No. 144, Accounting for the impairment or Disposal of Long-Lived Assets (“SFAS 144”).  Prior year condensed consolidated financial statements have been restated to present the operations of the life sciences business as discontinued operations.  See Note 5 for additional information.

On February 13, 2007, we effected a one-for-four reverse stock split of our common shares upon the filing of a Certificate of Amendment to our Articles of Incorporation with the California Secretary of State.  All impacted amounts included in the consolidated financial statements and notes thereto have been restated for the stock split.

Going Concern

While as of July 31, 2007, we have working capital of $1,953,000 and stockholders’ equity of  $766,000, we incurred significant losses from operations and used significant cash flow to fund operations during the most recent several fiscal years and through July 31, 2007.  Historically, we have relied upon outside investor funds to maintain our operations and develop our business. We anticipate we will continue to require funding from investors for working capital as well as business expansion during this fiscal year and we can provide no assurance that additional investor funds will be available on terms acceptable to us.  In addition, we have convertible debentures outstanding in the cumulative amount of $19,445,000 (which represents the face amount of the debentures and related accrued interest) as of July 31, 2007, which is due in May 2009 unless an Event of Default was to occur and the holder then declared an Event of Default.  See Note 8 for discussion of a potential waiver that may be required to remedy a potential Event of Default.  These conditions raise substantial doubt about our ability to continue operations as a going concern.

During the year ended April 30, 2007, and subsequently, we restructured our management team with the goal of refocusing our product lines, seeking joint venture partners and improving operating performance at the business segments through a focus on strategic products, increased efficiencies in business processes and improvements to the cost structure of each segment.  Despite these changes, our ability to continue as a going concern is dependent upon raising capital through debt or equity financing and ultimately by increasing revenue and achieving profitable operations. We can offer no assurance that we will be successful in our efforts to raise additional proceeds or achieve profitable operations.  The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.

6




NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Net Income (Loss) Per Share

Basic net income (loss) per share is computed using the weighted average number of common shares outstanding during the period.  Contingently issuable shares are included in the computation of basic net income (loss) per share when the related conditions are satisfied.  Diluted net income (loss) per share is computed using the weighted average number of common shares and potentially dilutive securities outstanding during the period.  Potentially dilutive securities consist of contingently issuable shares, the incremental common shares issuable upon conversion of convertible debt (using the “if converted” method) and shares issuable upon the exercise of stock options and warrants (using the “treasury stock” method).  Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive.

As of July 31, 2007, (a) a total of 5,119,000 outstanding stock options (excluding 3,550,000 stock options not deemed granted under US GAAP because the underlying plan or increase to the underlying plan has not been approved by our shareholders) and common stock warrants and (b) the unissued shares underlying our outstanding convertible debentures (with a cumulative outstanding face amount of $18,000,000 at July 31, 2007) were excluded from the diluted net loss per share calculation, as their inclusion would be anti-dilutive.  As of July 31, 2006, (a) a total of 5,790,261 outstanding stock options and common stock warrants and (b) the unissued shares underlying our outstanding convertible debentures (with a cumulative outstanding face amount of $18,062,500 at July 31, 2006) were excluded from the diluted net loss per share calculation, as their inclusion would be anti-dilutive.

During the three months ended July 31, 2007, we issued the following shares of common stock:

Description

 

Number of Common Stock Shares

 

Balance as of April 30, 2007

 

12,639,400

 

Shares issued for services

 

18,750

 

Balance as of July 31, 2007

 

12,658,150

 

 

The aforementioned equity transactions increased common stock in the accompanying condensed consolidated balance sheets by $29,000 for the three months ended July 31, 2007.

Recently Issued Accounting Standards

In July 2006, the Financial Accounting Standards Board (“FASB”) issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109 (“FIN 48”).  This interpretation clarifies the application of SFAS 109 by defining a criterion that an individual tax position must meet for any part of the benefit of that position to be recognized in an enterprise’s financial statements and also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods and disclosure.  FIN 48 requires the recognition of penalties and interest on any unrecognized tax benefits. Our policy is to reflect penalties and interest as part of income tax expense as they become applicable.  We adopted FIN 48 effective May 1, 2007.  No unrecognized tax benefits were recorded as of the date of adoption.  Due to certain “change in ownership” rules (as defined by the IRS), utilization of our federal net operating losses may be subject to certain annual limitations.  We have not completed a formal assessment as to the extent of such potential limitations. We file income tax returns in the U.S. federal and various state jurisdictions. We are no longer subject to U.S. federal and state and local

7




examinations by tax authorities for fiscal years prior to 2004.

In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (“SFAS 157”). SFAS 157 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. SFAS 157 is effective for our fiscal year commencing May 1, 2008, including interim periods within that fiscal year.  We are currently evaluating the impact of adopting SFAS 157 on our results of operations and financial condition.

In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and Financial Liabilities (“SFAS 159”).  SFAS 159 provides the option to report certain financial assets and liabilities at fair value, with the intent to mitigate volatility in financial reporting that can occur when related assets and liabilities are recorded on different bases.   SFAS 159 also amends SFAS No. 115, Accounting for Certain Investments in Debt and Equity Securities, by providing the option to record unrealized gains and losses on held-for-sale and held-to-maturity securities currently.  SFAS 159 is effective for our fiscal year commencing May 1, 2008, including interim periods within that fiscal year.  The implementation of FAS 159 is not expected to have a material impact on our results of operations or financial position.

NOTE 3 – FINANCIAL STATEMENT COMPONENTS

Inventories

Inventories consist of the following (in thousands):

 

July 31, 2007

 

April 30, 2007

 

Finished goods

 

$

647

 

$

497

 

Work in process

 

37

 

47

 

Materials and supplies

 

679

 

715

 

Total inventories

 

$

1,363

 

$

1,259

 

 

Property and equipment

Property and equipment consist of the following (in thousands):

 

 

July 31, 2007

 

April 30, 2007

 

Office furniture and equipment

 

$

361

 

$

331

 

Production equipment

 

8,373

 

7,613

 

Vehicles

 

191

 

191

 

Construction in process

 

779

 

854

 

Leasehold improvements

 

1,215

 

1,215

 

 

 

 

 

 

 

Accumulated depreciation and amortization

 

(4,953

)

(4,538

)

Total property and equipment, net

 

$

5,966

 

$

5,666

 

 

NOTE 4 –SEGMENT INFORMATION

We currently have three reportable segments: homeland security products, security services and semiconductor products and services.  Our homeland security products segment includes both operations regarding our Ion Mobility Spectroscopy (“IMS”) technology (see Note 11) and, through our 90%-owned subsidiary (SenseIt Corp, see Note 6), the

8




development of next-generation infrared imaging and night vision technology through our Development & Licensing Agreement with Lucent Technologies, Inc.  Our security services segment provides security and investigative services and is substantially comprised of the operations of Protection Plus Security Corporation (“PPSC”), which was acquired in May 2005.  Our semiconductor products and services segment provides 300-millimeter (and smaller diameter) silicon wafer reclaim and test products, wafer thinning and custom wafer products for the semiconductor industry.  Our segments are strategic business units, each of which consists of similar products or services.  They are managed separately because each segment requires different technology and marketing strategy and because each segment sells to different customers.  Reconciling items consist primarily of corporate assets or expenses that have not been allocated to a specific reportable segment and the assets of our former life sciences business which were categorized as discontinued operations prior to their sale in June 2007.  Prior period amounts have been reclassified to conform to current period presentation.

Information by segment is set forth below (in thousands):

 

Three Months Ended

 

 

 

July 31,

 

 

 

2007

 

2006

 

Segment revenues:

 

 

 

 

 

Homeland security products

 

$

 

$

 

Security services

 

3,756

 

3,877

 

Semiconductor products and services

 

2,113

 

2,909

 

Total

 

$

5,869

 

$

6,786

 

 

 

Three Months Ended

 

 

 

July 31,

 

 

 

2007

 

2006

 

Segment operating (loss) income:

 

 

 

 

 

Homeland security products

 

$

(1,321

)

$

(1,114

)

Security services

 

70

 

(274

)

Semiconductor products and services

 

(361

)

(199

)

Reconciling amounts (1)

 

(624

)

(2,366

)

Total

 

$

(2,236

)

$

(3,953

)

 

 

July 31,

 

April 30,

 

 

 

2007

 

2007

 

Total assets:

 

 

 

 

 

Homeland security products

 

$

1,210

 

$

1,943

 

Security services

 

6,689

 

6,127

 

Semiconductor products and services

 

8,612

 

9,068

 

Reconciling amounts (2)

 

1,747

 

1,822

 

Total

 

$

18,238

 

$

18,960

 

 

(1)   Reconciling amounts for the operating (loss) income information includes corporate expenses consisting primarily of corporate salaries and benefits, professional and consulting fees, investor relations costs, insurance and directors’ compensation.

(2)   Reconciling amounts for the total asset information includes corporate assets consisting primarily of cash and cash equivalents invested centrally, unamortized debt issuance costs and miscellaneous prepaid items as well as, for April 30, 2007, the assets of our

9




former life sciences business which were categorized as discontinued operations prior to their sale in June 2007.

NOTE 5 –DISCONTINUED OPERATIONS

During the three months ended January 31, 2007, we elected to discontinue the operation of our life sciences business and to put the assets and business up for sale.  We decided to sell this business as it no longer fit our long-term strategy and because of deteriorating business conditions in the historical, revenue producing products in the segment.  Accounting rules required us to treat the operations of the life sciences business as discontinued operations whereby the net financial impact of the operations of the business (including revenue) is combined into a single line item and prior periods are reclassified for this presentation. On June 19, 2007, we completed the sale of this business for total cash proceeds of $850,000, out of which we paid a selling fee of $45,000 and repaid a loan underlying production equipment in the amount of $40,000.

The business’ revenue, which is reported as discontinued operations in the accompanying condensed consolidated statements of operations, for the three months ended July 31, 2007 and 2006, was $101,000 and $616,000, respectively.  The business’ gain on operations of discontinued operations, net of income taxes, for the three months ended July 31, 2007 and 2006, was $37,000 and $36,000, respectively.

Following is a summary of the net assets sold on the closing date of June 19, 2007, and included in the condensed consolidated balance sheet as discontinued operations on April 30, 2007 (in thousands):

 

June 19,

 

April 30,

 

 

 

2007

 

2007

 

Cash

 

$

 

$

110

 

Accounts receivable

 

 

25

 

Inventory

 

8

 

66

 

Property and equipment, net

 

223

 

228

 

Other assets

 

56

 

62

 

Total assets

 

$

287

 

$

491

 

 

 

June 19,

 

April 30,

 

 

 

2007

 

2007

 

Accounts payable and accrued liabilities

 

$

 

$

33

 

Note payable

 

 

39

 

Total liabilities

 

$

 

$

72

 

 

NOTE 6 – INVESTMENT IN SENSEIT CORP

On October 26, 2006, we entered into a Class A Common Stock Purchase Agreement (the “Purchase Agreement”) with SenseIt Corp, a Delaware corporation (“SenseIt”), with the intent of accelerating next generation infrared imaging and night vision surveillance technology development and driving related commercialization activities in connection with our Development & Licensing Agreement with Lucent Technologies Inc. (currently known as Alcatel-Lucent), (the “Lucent Agreement” and “Lucent,” respectively).  The joint venture was established through our acquisition of an initial 90% ownership interest in SenseIt in exchange for assigning to SenseIt all of our interest under the Lucent Agreement, although we will continue to be jointly and severally liable with SenseIt to Lucent for amounts due to

10




Lucent under the assigned Lucent Agreement.  The assignment was approved by Lucent.

Pursuant to the Purchase Agreement, on October 27, 2006, we purchased shares of the Class A common stock of SenseIt in exchange for cash and other consideration, including, but not limited to, an assignment of all of our rights, title and interest in the Lucent Agreement.  As described above, we now have a 90% ownership interest in SenseIt.  Our ownership interest will be adjusted if SenseIt receives additional financing from third parties, and upon the occurrence of a Threshold Event.  The term “Threshold Event” is described in SenseIt’s Certificate of Incorporation, as amended, as the receipt by SenseIt of cumulative $20 million in certain equity financing.  At that time, the Class A common stock and Class B common stock will be converted into common stock, and the holder of the Class B common stock (held by the Christopher Toffales, chief executive officer of SenseIt and Chairman of the Board of Isonics Corporation) will be entitled to a 10% ownership interest.  The remaining 90% of the common stock outstanding will be allocated among the prior holders of common stock and Class A common stock.

In August 2007, we acquired an additional 10,000 shares of Class A common stock of SenseIt for consideration of $100,000.  Subsequent to this share purchase, we own 674,650 shares of Class A common stock of SenseIt.

We did not make the $1,000,000 payment that was due to Lucent on or before July 16, 2007.  As a result of not making this payment, Lucent may, after certain steps of notification and periods to cure have been exhausted, cancel the Lucent Agreement and all licenses granted to us thereunder or cease working on the project and then assess us a “start-up” fee if funding was to resume.  Effective July 26, 2007, we received official notification from Lucent that we failed to make the $1,000,000 payment to Lucent by July 16, 2007, and that in the event such non-payment continues for more than ten days, Lucent may at is discretion, suspend work on the development project.  On September 7, 2007, we received official notification from Lucent that they intend to suspend work on the development project if receipt of the $1,000,000 payment is not received by September 16, 2007, although Lucent also has the right to terminate the agreement.  We will not be able to make such payment by September 16, 2007, due to a lack of working capital. We can offer no assurance that if Lucent suspends the project that they will choose to restart the project even if we were to successfully raise the funds necessary to make the delinquent payment along with any start-up fee which may be required.  We also cannot offer any assurance that we will be able to raise the funds necessary to make all of the required payments to Lucent, or that the technology will be developed to a point where we want to continue to make such payments when due.  Additionally and subject to the aforementioned project risks and contingencies, SenseIt may need to seek outside financing to make payments to Lucent and, if so elected and subject to availability of financing, such outside financing would dilute our ownership interest in SenseIt.

NOTE 7 – EQUITY

2005 Stock Option Plan

In May 2007, our Board of Directors approved a resolution increasing the shares available for issuance to 2,875,000, an increase of 2,000,000 shares.  Any options granted from this increased allotment will not be exercisable until approved by our shareholders and we expect to include the proposal to approve this plan as an item to be considered at our next annual meeting of shareholders.  Due to a lack of working capital, we have decided to postpone our annual shareholder meeting of shareholders from our earlier contemplated timing of November 2007 to a later period.

11




Equity Instruments Issued for Services

In May 2007, we entered into a consulting agreement with CEOcast, Inc. to provide investor relations services.  The compensation terms of the agreement included the issuance of 18,750 shares of our common stock, which was valued at $29,000.  The common stock was recorded as prepaid consulting expense and will be amortized ratably over the service period of six months.  For the three months ended July 31, 2007, we recognized $5,000 of selling, general and administrative expense related to the shares of common stock issued under the agreement.

In June 2007, we granted options to purchase 200,000 shares of our common stock to Sound Business Solutions, Inc., an entity whose principal has been providing management services in our semiconductor products and services segment.  This option was granted pursuant to our 2005 Stock Option Plan.  The stock options granted to Sound Business Solutions Inc. are subject to the following vesting schedule: 66,667 shares vested immediately upon grant; 66,667 shares vested on September 7, 2007; and 66,666 shares vest on January 31, 2008.  The stock options granted to Sound Business Solutions Inc. are exercisable through June 18, 2011, at $1.45 per share.  Options to purchase 50,000 shares (valued at $53,000 using the Black-Scholes pricing model) are currently exercisable while options to purchase 150,000 shares are subject to our shareholders approving the aforementioned increase to the cumulative shares issuable under the 2005 Stock Option Plan.  A charge in the amount of $28,000 was recognized as a selling, general and administrative expense for the three months ended July 31, 2007.  This charge related to the portion of the fair value of the currently exercisable option to purchase 50,000 shares that is associated with work performed in the reporting period.  Under SFAS 123(R), a stock option is not considered granted for accounting purposes until stockholder approval is obtained (unless such approval is deemed a formality, which is not the case for the proposed increase to the 2005 Stock Option Plan).  As such, no expense has been recognized in the condensed consolidated financial statements related to the option to purchase 150,000 shares of common stock.  When and if the increase to the 2005 Stock Option Plan is approved by the shareholders, we expect a stock-based compensation charge to be incurred based on the fair value of the stock options on the date of shareholder approval.

NOTE 8 – BORROWINGS

Capital Lease

In May 2007, we entered into a capital lease to finance equipment to be used in production by our semiconductor products and services segment.  The lease is in the principal amount of $628,000, bears a nominal interest rate of 16%, has a term of 36 months and includes a bargain purchase option whereby we have the right subsequent to the expiration of the lease term to purchase the asset under lease for no more than 5% of the original equipment cost.  Additionally, we issued the lessor a common stock warrant (valued at $39,000 using the Black-Scholes pricing model) to purchase 40,000 shares of common stock at $1.50 per share.  The common stock warrant vested immediately, expires on May 28, 2010, and is being amortized to interest expense over the term of the lease.

April 2007 Debenture

In April 2007, we issued to YA Global Investments, L.P. (“YA Global”), formerly known as Cornell Capital Partners, LP, a convertible debenture with a face amount of $2,000,000 (the “April 2007 Debenture”) along with detachable common stock warrants.  For the three months ended July 31, 2007, using the effective interest method we amortized $37,000 of the discount on the April 2007 Debenture to interest expense.  As of July 31, 2007, the April 2007 Debenture has an outstanding face amount of $2,000,000 and is recorded in our condensed consolidated balance sheets at a carrying amount (net of discount) of $1,701,000.  We also recorded accrued interest on the April 2007 Debenture in the amount of $66,000 for the three months ended July 31, 2007.  As of July 31, 2007, cumulative

12




accrued interest is $80,000; such accrued interest is included in other long-term liabilities in the condensed consolidated balance sheets and is due upon maturity of the April 2007 Debenture in May 2009.

We are contractually required to obtain shareholder approval of this transaction by no later than November 30, 2007, including the ability to issue a maximum of 10 million shares upon conversion of the April 2007 Debenture and 250,000 shares for issuance upon exercise of the April 2007 Debenture Warrant.  Due to a lack of working capital, we have decided to postpone our annual meeting of shareholders to a time subsequent to November 30, 2007.  If, as expected, we do not obtain shareholder approval of the April 2007 Debenture by November 30, 2007, and do not receive a waiver from the holder of the April 2007 Debenture, the holder of that debenture may declare an Event of Default.  Remedies for an Event of Default include the option to accelerate payment of the full principal amount of the April 2007 Debenture, together with interest and other amounts due (a cumulative amount of $2,080,000 at July 31, 2007), to the date of acceleration and the holder will have the right to request such payment in cash or in shares of our common stock.  If the holder of the April 2007 Debenture declares an Event of Default, it is unlikely that we will be able to cure the default or contest any efforts that the holder may take to foreclose against its security interest in substantially all of our assets.

2006 Convertible Debentures

In May, June and November 2006, we issued to YA Global convertible debentures with a cumulative face amount of $16,000,000 (the “2006 Debentures”) along with detachable common stock warrants.  For the three months ended July 31, 2007, using the effective interest method we amortized $708,000 of the discount on the 2006 Debentures to interest expense.  As of July 31, 2007, the 2006 Debentures have a cumulative outstanding face amount of $16,000,000 and are recorded in our condensed consolidated balance sheets at a carrying amount (net of discount) of $7,673,000.  We also recorded accrued interest on the 2006 Debentures in the amount of $524,000 for the three months ended July 31, 2007.  As of July 31, 2007, cumulative accrued interest is $1,375,000; such accrued interest is included in other long-term liabilities in the condensed consolidated balance sheets and is due upon maturity of the 2006 Debentures in May 2009.

Certain events, as defined in the 2006 Debenture agreements, may allow the 2006 Debentures holder to declare an Event of Default.  One default provision included in the 2006 Debenture agreements provides that the holder of the 2006 Debentures can declare an Event of Default under the 2006 Debentures if we are declared in default under any other debenture or other financial liability instrument in excess of $500,000.  If the holder of the April 2007 Debenture were to declare an Event of Default under that debenture (as discussed previously within this footnote), the holder of the 2006 Debentures could declare an Event of Default under the 2006 Debentures.  Remedies for an Event of Default, include the option to accelerate payment of the full principal amount of the Debentures, together with interest and other amounts due (a cumulative amount of $17,375,000), to the date of acceleration and the holder will have the right to request such payment in cash or in shares of our common stock.  If the holder of the 2006 Debentures declares an Event of Default, it is unlikely that we will be able to cure the default or contest any efforts that the holder may take to foreclose against its security interest in substantially all of our assets.

NOTE 9 – COMMITMENTS AND CONTINGENCIES

As of July 31, 2007, we had commitments outstanding for capital expenditures of approximately $100,000.

13




NOTE 10 - RELATED PARTY TRANSACTIONS

We have a research and development agreement with Institut fur Umwelttechnologien GmbH (“IUT”), an equity method investee of which we own 30%.  We funded $78,000 and $460,000 under this agreement for the three months ended July 31, 2007 and 2006, respectively (and a total of $2,986,000 since entering into our first research and development agreement in June 2004).  All funded payments have been included as research and development in the accompanying condensed consolidated statements of operations.

NOTE  11 – SUBSEQUENT EVENTS

Certain events occurring subsequent to July 31, 2007, are discussed within other notes to the condensed consolidated financial statements.

In August 2007, we elected to suspend the development, manufacture and sale of our IMS-based products.  The suspension was due primarily to a lack of working capital but we have also had difficulty competing in the market space.  We will continue to seek alternatives towards finding a means of monetizing our IMS-based investment, including the development of a strategic partnership or an outright sale of the technology.  It is unclear as to when (if at all) we will resume activity on our IMS-based products and we can offer no assurance that we will be able to monetize any portion of our IMS-based investment.  We are currently evaluating the impact of this decision on the carrying value of certain assets recorded in our condensed consolidated balance sheets.

14




Item 2:  Management’s Discussion and Analysis of Financial Condition and Results of Operations

Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  These forward-looking statements generally are identified by the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “project,” “will,” “plan,” “will continue,” “will likely result” and similar expressions.  Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements.  A detailed discussion of these and other risks and uncertainties that could cause actual results and events to differ materially from such forward-looking statements is included in the section entitled “Risk Factors” (refer to Item 1A of Part II).  We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

General Discussion

We are focused on the development and provision of homeland security products and services and the manufacture of 300-millimeter (and smaller diameter) silicon wafer reclaim and test products, wafer thinning and custom wafer products for the semiconductor industry.  During the past several years, our operations have been characterized by working capital and cash flow shortfalls, and the need for a significant amount of third party investment to enable us to meet our financial obligations.  Although we have met our obligations to date (except for the $1,000,000 payment that was due to Lucent on July 16, 2007), we have frequently been required to allocate our available cash among various obligations.  During the three months ended July 31, 2007 and subsequently, we have also refocused our operations and have attempted to reduce significantly our expenses, including the cash flow necessary to pay our corporate and divisional overhead.

In June 2007 we sold our life sciences business (which supplied isotopes for life sciences and health-care applications) as it no longer fit our long-term strategy for building a sustainable and profitable homeland security and semiconductor company and because of deteriorating business conditions in the historical, revenue producing products in this business.

In August 2007, we elected to suspend the development, manufacture and sale of our IMS-based products.  The suspension was due primarily to a lack of working capital but we have also had difficulty competing in the market space.  We will continue to seek alternatives towards finding a means of monetizing our IMS-based investment, including the development of a strategic partnership or an outright sale of the technology.  It is unclear as to when (if at all) we will resume activity on our IMS-based products and we can offer no assurance that we will be able to monetize any portion of our IMS-based investment.

We continue to work towards developing a next-generation infrared imaging and night vision surveillance technology with our partner Lucent but as discussed further below, we have not been able to make our required development payments to Lucent.  As a result of not making our required development payments on a timely basis, Lucent has the right (until we make the outstanding payment) to suspend or terminate the project without recourse to us.  We were recently notified by Lucent that if we did not make the outstanding $1,000,000 payment by September 16, 2007, Lucent intends to suspend work on the development project, although Lucent also has the right to terminate the agreement.  We will not be able to make such payment by September 16, 2007, due to a lack of working capital.  We continue to seek financing in order to resume the project but we can offer no assurance that we will be successful or, if successful, Lucent will chose to restart the project.  If Lucent were to terminate the project we will likely lose our entire investment in SenseIt as it will become valueless.

15




Although our common stock is quoted on the Nasdaq Capital Market, as of July 31, 2007, our stockholders’ equity was $766,000 and thus we have failed to meet the listing requirement of either stockholders’ equity of at least $2,500,000 or market value of listed securities of at least $35,000,000.  As a result, upon filing this Form 10-Q we expect to receive a notice from Nasdaq for failure to comply with this requirement.  In addition, our per-share bid price is (and has been for some time) below the required $1.00 minimum requirement and as a result we expect to receive a notice from Nasdaq for failure to comply with this requirement as well.  Given our current lack of working capital, ongoing operating losses and difficulty in obtaining additional financing it is likely that we will not be able to cure these deficiencies.  If we are not able to cure such deficiencies, it most likely will result in our delisting from the Nasdaq Capital Market.

Liquidity and Capital Resources

We have had working capital shortages in the past and, although we raised capital totaling more than $45,800,000 (net of expenses and $4,100,000 of payments related to our 8% Debentures) since May 1, 2004, we have generated significant losses, which have impacted working capital.  As of July 31, 2007, our condensed consolidated balance sheet reflects working capital of $1,953,000.  In addition, as a result of our continued operating losses and projected declining working capital balances during the year ending April 30, 2008, the auditors report included with our financial statements for the year ended April 30, 2007, included an explanatory paragraph indicating substantial doubt about our ability to continue as a going concern.

Based on the amount of capital we have remaining and our expected negative cash flow from operations and investing activities, we anticipate that we will not be able to positively impact our working capital unless we are able to substantially increase our revenues or reduce our expenses thereby generating positive cash flow from operations and (ultimately) operating income.  We believe we have sufficient working capital to finance our anticipated operations and projected negative cash flow only into our quarter ending January 31, 2008, unless we are able to achieve significant additional financing.  Because of the potential dilution associated with the outstanding debentures and the holder’s security interest in substantially all of our assets, we believe that it is unlikely that we will be able to obtain additional financing unless we are able to reach an accommodation with our existing debenture holder.

We are contractually required to obtain shareholder approval of the April 2007 Debenture (held by YA Global) by no later than November 30, 2007.  Due to a lack of working capital, we have decided to postpone our annual meeting of shareholders to a time subsequent to November 30, 2007.  If, as expected, we do not obtain shareholder approval of the April 2007 Debenture by November 30, 2007, and do not receive a waiver from the holder of the April 2007 Debenture, the holder of that debenture may declare an Event of Default.  Further, a default provision in the 2006 Debentures (also held by YA Global) would allow the holder to also declare an Event of Default of that debenture agreement if we were declared in default of the April 2007 Debenture.  Remedies for an Event of Default under all convertible debenture agreements include the option to accelerate payment of the full principal amount of the respective debenture, together with interest and other amounts due (a cumulative $19,455,000 as of July 31, 2007), to the date of acceleration and the holder will have the right to request such payment in cash or in shares of our common stock.  If the holder declares default, it is unlikely that we will be able to cure the default or contest any efforts that the holder may take to foreclose against its security interest in substantially all of our assets.

See additional discussion of liquidity and capital resources in the Liquidity and Capital Resources section included further below in this Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Overview

During the year ended April 30, 2007, and the three months ended July 31, 2007, we generated sales from stable and radioactive isotopes, silicon wafer reclaim

16




and test products, wafer thinning and custom wafer products for the semiconductor industry, although sales from stable and radioactive isotopes were reported as discontinued operations in the accompanying condensed consolidated statements of operations as described below. Additionally, as a result of the acquisition of PPSC in May 2005, we also generated revenues from providing security services for leading businesses and institutions in healthcare, education, retail, manufacturing, banking and the art world.  For information about segment revenue, refer to Note 4 (Segment Information) to the condensed consolidated financial statements located in Item 1: Financial Statements.

In June 2007 we sold our life sciences business (which supplied isotopes for life sciences and health-care applications) as it no longer fit our long-term strategy for building a sustainable and profitable homeland security and semiconductor company and because of deteriorating business conditions in the historical, revenue producing products in this business.  Accounting rules required us to treat the operations of the life sciences business as discontinued operations whereby the net financial impact of the operations of the business (including revenue) is combined into a single line item and prior periods are reclassified for this presentation.  Revenue for the life sciences business, reported in the single line item of gain on operations of discontinued operations, net of income taxes, was $101,000 and $616,000 for the three months ended July 31, 2007 and 2006, respectively.

The following is a more specific discussion of our current operations.

Homeland Security

Isonics Homeland Security and Defense Corporation (“HSDC”) focuses the majority of our efforts in the homeland security sector.  These efforts included entry into the security services market through our acquisition of PPSC in May 2005, acquisition and (prior to August 2007) development of our IMS detection technology and our entry into an agreement (currently in default) with Lucent and a 90% owned joint venture named SenseIt Corp to develop innovative infrared imaging and night vision surveillance technology.   HSDC’s ownership also includes our 30% minority interest in IUT.  The following is a detail of each of our product lines within our homeland security operations:

Security Services - In May 2005, we acquired PPSC, a provider of security services located in New York, New York.  Since the effective date of the acquisition, PPSC has delivered significant revenue to our condensed consolidated financial statements and has provided gross margin of approximately 22% of revenues for the three months ended July 31, 2007.

During the fourth quarter of the year ended April 30, 2007, and the three months ended July 31, 2007, we implemented cost cutting initiatives that were expected to positively impact the results of PPSC’s operations.  Additionally we initiated plans to improve operating margins at PPSC by focusing on customers that are willing to pay for premium security services, a market in which we believe that PPSC is able to differentiate itself from its peers.  As a result, we have and will exit lower-margin business areas for premium accounts that prefer higher quality of service.  As a result of the impact of certain of these cost cutting initiatives, the segment generated operating income of $70,000 for the three months ended July 31, 2007, as compared to an operating loss of $(274,000) for the three months ended July, 2006.  For the three months ended July 31, 2007 and 2006, the operating loss includes non-cash amortization of acquisition-related customer intangibles and stock-based compensation expense in the amount of $45,000 and $90,000, respectively.

While we believe that these cost cutting initiatives and refocused sales and marketing efforts will enable PPSC to report positive operating income for the year ending April 30, 2008, we can offer no assurance that this will actually occur.

PPSC has successfully obtained its federal Government Contract Schedule (“GSA Schedule”) for security services.  Although we have selectively

17




pursued and continue to pursue government contracts in addition to commercial contracts, we have not acquired any federal government security contracts to date and we can offer no assurance that we will be able to do so.

Detection Technology – During our year ended April 30, 2007 and through July 31, 2007, we offered our existing IMS-based products (the panel-mounted IMS and EnviroSecure), although we have not engaged in any significant marketing efforts for these products since late in calendar year 2006.  Although we continued to offer EnviroSecure™, a system that can monitor and identify chemical weapons and toxic substances in the air in a variety of venues including airports, mass transit facilities, sports venues and public and private sector office buildings, we did not make any sales of this product or engage in any significant marketing activities.  Our sales of the panel-mounted IMS product have been extremely limited and have resulted in deferred revenue that we have not yet substantially recognized. We have not recently engaged in any marketing efforts for that product, and we do not intend to recommence any marketing efforts until (if ever) we are adequately capitalized, have a commercial product and have identified a market.

During the latter half of the year ended April 30, 2007, we redefined and refocused the operations of HSDC to focus on the development of partnerships with leading prime contractors in the security and defense, industrial and transportation markets, although we have not yet developed any such partnerships.  By working with these types of partners, we believed that we would be able to more effectively and efficiently complete the development of our IMS-based products with the goal of incorporating them into the products and systems of our partners.  If we were successful in developing these types of strategic partnerships, we believed that we would be in a better position to compete with the current industry leaders through leveraging the marketing arms and customer bases of these partners.  This change in strategic direction delayed the time frame for significant product sales but we were hopeful that it would allow for a significant reduction in development costs and a greater penetration of the market in the future.

In August 2007, we elected to suspend the development, manufacture and sale of our IMS-based products.  The suspension was due primarily to a lack of working capital but we have also had difficulty competing in the market space.  We will continue to seek alternatives towards finding a means of monetizing our IMS-based investment, including the development of a strategic partnership or an outright sale of the technology.  It is unclear as to when (if at all) we will resume activity on our IMS-based products and we can offer no assurance that we will be able to monetize any portion of our IMS-based investment.

In November 2005, we signed a development agreement with DualDraw LLC (“Dual Draw”), a manufacturer of air quality equipment.  Under this agreement, we worked to incorporate our panel-mounted IMS-based system into the DualDraw mailroom inspection workstation, a downdraft workstation that keeps toxic substances away from the breathing zone of mailroom workers who are sorting or opening mail and captures such substances with a HEPA (high efficiency particulate air) filtration system.  The incorporation of our IMS capability provides an alarm if certain toxic or explosive substances are detected.  We completed seven commercial installations of our panel-mounted IMS-based product in the AirChx system manufactured by Dual Draw during the year ended April 30, 2007, as well as an additional eight units during the three months ended July 31, 2007.  We have not received payment from DualDraw for the latter eight units, and our anticipated revenue for all units are primarily being classified as deferred revenue pending completion of certain tasks. We do not expect to receive any more purchase orders from DualDraw for our panel-mounted IMS-based product.

Infrared Imaging Technology – In December, 2005, we approved a development plan that resulted in us becoming obligated under the Lucent Agreement we entered into with Lucent in September 2005 which, in October 2006, we assigned to our 90% owned subsidiary, SenseIt, which is described in more detail below.  Under the Lucent Agreement, we are attempting to develop a next-generation infrared imaging and night vision surveillance technology based on Lucent’s micro electro-mechanical systems (“MEMS”) technology under development at its nanotechnology fabrication facility.  Infrared technology, which converts infrared radiation in the non-visible spectrum, such as body

18




heat, into a visible image, is commonly found in both commercial and military/homeland security applications including night vision goggles and cameras, rifle scopes and threat detection devices used to identify concealed weapons or explosives.  The MEMS approach to infrared imaging, if successful, may lead to products which we believe will at least equal the performance of, with a lower power consumption and price than, products currently available in the marketplace today.  Additionally, a MEMS-based product may also provide for cost efficiencies in the manufacturing process.  The development plan contemplates a proof-of-concept during calendar year 2007, followed by steps towards commercialization, though we can provide no assurance that a commercially attractive product will ultimately be available.

In October 2006, we acquired a 90% interest in SenseIt in exchange for assigning to SenseIt all of our interest under the Lucent Agreement, although we will continue to be jointly and severally liable with SenseIt to Lucent for amounts due to Lucent under the assigned Lucent agreement. The remaining 10% of SenseIt is owned by Christopher Toffales (our Chairman of the Board), who also serves as President and Chief Executive Officer of SenseIt.

We have paid Lucent $6,000,000 of the $12,000,000 due, and we have paid an additional $750,000 to SenseIt for its working capital purposes or on behalf of SenseIt during initial incorporation.

We are currently seeking additional financing to allow us to fund SenseIt so that SenseIt can make its delinquent and future contractual development payments to Lucent.  Because SenseIt has failed to make a mandatory $1,000,000 payment to Lucent (which payment was due July 16, 2007), Lucent has advised us that it intends to suspend work on the project, although Lucent may also terminate the agreement.  There can be no assurance that once suspended, Lucent will ever agree to recommence work on the project.  If we are unable to arrive at an agreement with Lucent to recommence work on the project and raise sufficient funds to enable us to cure our delinquency with Lucent, we will likely lose our entire investment in SenseIt as it will become valueless.

We cannot offer any assurance that we will be able to raise the funds necessary to make all of the required payments to Lucent, or that the technology will be developed to a point where we want to continue to make such payments when due.  Additionally and subject to the aforementioned project risks and contingencies, SenseIt may need to seek outside financing to make payments to Lucent and, if so elected, such outside financing would dilute our ownership interest in SenseIt.  Lastly, although we are hopeful of a positive outcome, we can offer no assurance that the development activity underway with Lucent and SenseIt will yield technologically relevant and commercially viable products.

In addition to Lucent’s right to terminate the project because of SenseIt’s non-payment, SenseIt has the right to terminate the development project for any reason (including if the development work is not proceeding up to our expectations) from time-to-time, so long as termination is prior to the first commercial sale of a licensed product.  Additionally, upon the commencement of commercial sales, if ever, we would be obligated to pay royalties based on revenue, potentially a sales referral fee based on revenue and also an annual exclusivity payment (to Lucent) to maintain our exclusive rights to the developed technology.

Semiconductor Products and Services

Our semiconductor operations, based in Vancouver, Washington, showed continued operational and financial improvement during the years ended April 30, 2007 and 2006, although we have experienced a softening of demand for our products and services during the three months ended July 31, 2007 and subsequently (as discussed further below).  The segment generated operating income for the year ended April 30, 2007, in the amount of $326,000 (which includes a non-cash charge of $122,000 for stock-based compensation expense) as compared to an operating loss for the year ended April 30, 2006, in the amount of $(5,151,000).  The positive operating income results primarily from our ongoing effort to reduce our reliance on low margin small diameter products and diversify into higher margin 300-millimeter products and services, wafer thinning and custom wafer products.

19




The large-diameter wafer segment has become one of the fastest growing segments of the silicon wafer market and the revenues and gross margins associated with the services are greater than those associated with the small diameter market.   As a result of our strategic realignment, revenue from 300-millimeter services comprised approximately 46% of segment revenue for the three months ended July 31, 2007 ($970,000 of revenue) and 54% of segment revenue for the year ended April 30, 2007 ($7,049,000 of revenue), as compared to approximately 36% of segment revenue for the year ended April 30, 2006 ($2,053,000 of revenue).  At the same time, there has also been a focus on operational efficiency and effectiveness, which has resulted in increased productivity and processing yields.  Further, we continue to gain new customers and are also in the process of attempting to qualify our product at others.

While we reported significant revenue and operating income growth in our semiconductor operations for the year ended April 30, 2007, many of our top semiconductor customers experienced weakened business results in recent quarters.  In addition, some customers have reported inventory buildup in reclaim and/or test products.  As a result of these two factors, we have recently seen a slowdown in orders of reclaim and test materials, which has had a negative impact on our operations.

The slowdown significantly impacted our revenues, results of operations and cash flows for the three months ended July 31, 2007, in which we generated an operating loss of $(361,000) as compared to $(199,000) for the three months ended July 31, 2006.  The impact of the slowdown in orders on our business is magnified when the results are compared to the three months ended April 30, 2007, whereby we generated operating income of $286,000.

In order to minimize the effect of the slowdown, we have implemented many cost cutting measures and will continue to do so.  It is unclear as to when our customers’ demand will rebound but we believe that this is a relatively short-term condition and are hopeful that we will begin to see a recovery during the next six months.  While we continue to aggressively pursue and add new customers to mitigate the underlying uncertainties with our existing customer base, we expect to reflect a significant reduction in revenue for the three months ended October 31, 2007 (as compared to the three months ended October 31, 2006) and the reporting of an operating loss for the segment.  We continue to monitor the situation closely and while we believe that we will see improving financial results in this operating segment (over the long-term), we cannot offer any assurance that we will be able to regain or sustain operating profitability in future periods.

General

Our consolidated revenues in the future will depend primarily on our success in developing and selling products in the homeland security and continued performance in the semiconductor markets.  Our profitability will be dependent upon our ability to manage our costs and to increase our revenues in all of our business segments.  However, we can offer no assurance that we will be able to increase our revenues or our profitability.

Results of Operations

The following table sets forth, for the periods indicated, condensed consolidated statements of operations data expressed as a percentage of revenues.  The table and the discussion below should be read in conjunction with the condensed consolidated financial statements and the notes thereto appearing elsewhere in this report.  In January 2007, we elected to discontinue the operation of our life sciences business and to put the assets and business up for sale (which was sold in June 2007).  As a result, we reclassified the operations of our life sciences business as discontinued operations.  Prior year information has been reclassified to conform with the current year presentation.

20




 

 

Three Months Ended

 

 

 

July 31,

 

 

 

2007

 

2006

 

 

 

 

 

 

 

Revenues

 

100.0

%

100.0

%

Cost of revenues

 

85.2

 

82.0

 

Gross margin

 

14.8

 

18.0

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

Selling, general and administrative

 

35.6

 

55.5

 

Research and development

 

17.3

 

20.7

 

Total operating expenses

 

52.9

 

76.2

 

Operating loss

 

(38.1

)

(58.2

)

 

 

 

 

 

 

Other income (expense), net

 

(23.9

)

22.7

 

Loss from continuing operations before income taxes and elimination of minority interest

 

(62.0

)

(35.5

)

Income tax expense

 

 

 

Minority interest in operations of consolidated subsidiary

 

1.7

 

 

Loss from continuing operations

 

(60.3

)

(35.5

)

Gain on discontinued operations, net of income taxes

 

9.4

 

0.5

 

NET LOSS

 

(50.9

)%

(35.0

)%

 

Revenues

Revenues from our security services and semiconductor products and services segments decreased for the three months ended July 31, 2007, as compared to the same period of our prior fiscal year, as described in the following table:

 

Three Months Ended

 

 

 

July 31,

 

 

 

2007

 

2006

 

Homeland security products

 

$

 

$

 

Security services

 

3,756,000

 

3,877,000

 

Semiconductor products and services

 

2,113,000

 

2,909,000

 

Total

 

$

5,869,000

 

$

6,786,000

 

 

The decrease in revenue from the security services segment for the three months ended July 31, 2007, is due to the net loss of several mainly lower margin security services contracts during the current period.  We continue to market our services aggressively by seeking premium accounts that prefer higher quality of service.  While we anticipate that we will be able to grow revenue in this segment by securing additional new security contracts in our PPSC subsidiary and retaining existing customers under contract currently with PPSC, we cannot provide any assurance that we will be able to do so.

While we reported significant revenue and operating income growth in our semiconductor operations for the year ended April 30, 2007, many of our top semiconductor customers experienced weakened business results in recent quarters.  In addition, some customers have reported inventory buildup in reclaim and/or test products.  As a result of these two factors, we have recently seen a slowdown in orders of reclaim and test materials, which has had a negative impact on our operations.

21




The slowdown significantly impacted our revenues, which decreased by approximately 27% to $2,113,000 for the three months ended July 31, 2007, as compared to $2,909,000 for the three months ended July 31, 2006.  The impact of the slowdown in orders on our business is magnified when the results are compared to the three months ended April 30, 2007, whereby we recorded revenues of $3,686,000.

In order to minimize the effect of the slowdown, we have implemented many cost cutting measures and will continue to do so.  It is unclear as to when our customers’ demand will rebound but we believe that this is a relatively short-term condition and are hopeful that we will begin to see a recovery during the next six months.  While we continue to aggressively pursue and add new customers to mitigate the underlying uncertainties with our existing customer base, we expect to reflect a significant reduction in revenue for the three months ended October 31, 2007 (as compared to the three months ended October 31, 2006) and the reporting of an operating loss for that segment.  We continue to monitor the situation closely and while we believe that we will see improving financial results in this operating segment (over the long-term), we cannot offer any assurance that we will be able to regain or sustain operating profitability in future periods.

Our homeland security products segment recorded no revenue for the three months ended July 31, 2007 and 2006.  The proceeds related to the installation of eight commercial units of our panel-mounted IMS-based product in the AirChx system manufactured by Dual Draw during the three months ended July 31, 2007 have been classified as deferred revenue pending completion of certain tasks.

In August 2007, we elected to suspend the development, manufacture and sale of our IMS-based products.  The suspension was due primarily to a lack of working capital but we have also had difficulty competing in the market space.  We will continue to seek alternatives towards finding a means of monetizing our IMS-based investment, including the development of a strategic partnership or an outright sale of the technology.  It is unclear as to when (if at all) we will resume activity on our IMS-based products and as a result, we don’t anticipate any sales of our IMS-based products during the three months ended October 31, 2007.

Although we have diversified our sources of revenue, we continue to have concentrations of revenue with certain customers.  For the three months ended July 31, 2007, two security services customers accounted for 18% and 13% of revenues, respectively, and one semiconductor products and services customer accounted for 11% of revenues as compared to the three months ended July 31, 2006, in which two security services customers accounted for 15% and 10% of revenues, respectively, and one semiconductor products and services customer accounted for 23% of revenues.  Significant reductions in sales to any of these large customers have had, and may in the future have, an adverse effect by reducing our revenues and our gross margins.  Present or future customers could terminate their purchasing patterns with us or significantly change, reduce or delay the amount of products or services ordered from us.

Gross Margin

Our gross margin decreased for the three months ended July 31, 2007, as compared to the same period of our prior fiscal year, both on a dollar amount and on a percentage of revenues, as reflected in the following table:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

871,000

 

$

1,219,000

 

Percent of revenues

 

14.8

%

18.0

%

 

The decrease in gross margin on a percentage basis is due primarily to the downturn in our semiconductor products whereby the downturn has lead to a significant decrease in revenue which has forced us to allocate our fixed facility costs over a lower base, correspondingly decreasing gross margins on a percentage basis.  To a lesser extent, the decrease on a percentage basis is also due to the provision of lower prices in order to

22




obtain new or keep existing business.

The decrease in gross margin on a dollar basis is due mainly to the decrease in revenue for our semiconductor products and services segment along with the net loss of several mainly lower margin security services contracts during the current period.  As a result of the slowdown in orders of reclaim and/or test wafers during the three months ended July 31, 2007, and into the three months ending October 31, 2007 (as discussed above) it is currently unclear if we will be successful in maintaining or increasing quarterly gross margins (on a dollar basis) in our semiconductor products and services segment for the year ending April 30, 2008.

On a dollar basis, gross margin is expected to increase correspondingly with increases in revenue, if any, with dependencies on customer and supplier pricing.  Our ability to positively impact consolidated gross margin will in a large part be dependent upon our ability to grow sales in our security service segment through increased sales of security services and in our semiconductor products and services segment through increased sales of 300-millimeter products and services and wafer thinning services.

On a percentage of revenue basis, in general we anticipate that the gross margin percentage in our security services segment (within 1-2 percentage points) will remain relatively stable.  As a result of the current downturn which has and may lead to more increased competition and lower prices, our semiconductor products and services segment will most likely experience a decrease in gross margins as a percentage of revenues during the year ending April 30, 2008, as compared to the year ended April 30, 2007.  Due to fixed facility costs included in cost of revenues in the semiconductor products and services segment, the gross margin percentage is particularly sensitive to volume and revenue changes.

Selling, General and Administrative Expenses

Our selling, general and administrative expenses decreased both as a dollar amount and as a percentage of revenue for the three months ended July 31, 2007, as compared to the same respective period of our prior fiscal year, as reflected in the following table:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

2,090,000

 

$

3,768,000

 

Percent of revenues

 

35.6

%

55.5

%

 

The $1,678,000 decrease in selling, general and administrative expenses for the three months ended July 31, 2007, compared to the same period in the prior year is attributable to a combination of factors, including:

·                  approximately $425,000 due to a decrease in staffing and expenditures at the corporate office;

·                  approximately $320,000 due to a decrease in staffing and expenditures in the security services segment;

·                  approximately $300,000 due to a decrease in staffing and operations in the homeland security products segment;

·                  inclusion in the three months ended July 31, 2006, of a noncash charge in the amount of $357,000 related to the amendment to the number of shares issuable and exercise price of certain warrants with ratchet provisions;

·                  an approximate $280,000 decrease in noncash stock-based compensation expense.

Although we are actively focused on reducing selling, general and administrative expenditures, we anticipate that our reported selling, general and administrative expenses will increase during fiscal year 2008 due primarily to stock-based incentive compensation issued as part of a series of management changes made in February 2007.  No expense has been

23




recognized to date related to the option grants made in February 2007 because the new underlying stock option plan or the proposed increase to an existing underlying stock option plan have not been approved by shareholders.  There can be no assurance that anticipated selling, general and administrative expenses will result in increased revenues from product sales.

Research and Development Expenses

Our research and development expenses decreased on both a dollar and a percentage of revenues basis for the three months ended July 31, 2007, as compared to the same period of our prior fiscal year, as reflected in the following table:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

1,017,000

 

$

1,404,000

 

Percent of revenues

 

17.3

%

20.7

%

 

The majority of research and development expenses for the three months ended July 31, 2007 and 2006 relate primarily to the development of next-generation infrared imaging and night vision surveillance technology through our Lucent relationship and our IMS technology.

Historically a significant amount of the research and development on the IMS technology was performed by IUT.  This amount however was reduced significantly for the three months ended July 31, 2007, as we had changed our focus to a strategic, customer-based focus instead of a product orientation. We funded $78,000 and $460,000 under our agreement with IUT for the three months ended July 31, 2007 and 2006, respectively.  As a result of the suspension of the development, manufacture and sale of our IMS-based products as described above, we expect that future research and development expense with IUT to be minimal.

In December 2005, we approved a development plan with Lucent that obligated us under the Lucent Agreement.  Under the Lucent Agreement, we are attempting to develop a next-generation infrared imaging and night vision surveillance technology.  In October 2006, we acquired a 90% interest in SenseIt in exchange for assigning to SenseIt all of our interest under the Lucent Agreement (such assignment was approved by Lucent) and we also entered into a new statement of work with Lucent (which was also transferred to SenseIt).  Inasmuch as SenseIt has failed to meet its payment obligations under the agreement with Lucent, SenseIt may lose its rights under that agreement.  Even if SenseIt (with funding from Isonics or other sources) is able to resume operations under the Lucent agreement, we can provide no assurance that a commercially attractive product will ultimately be available.

For the three months ended July 31, 2007 and 2006, we recognized research and development expense related to the Lucent Agreement of $833,333.  Under the Lucent agreement, SenseIt must provide funding of $1,000,000 per quarter in development funding for the next five quarters (in addition to funding the payment not made that was due on or before July 16, 2007) or risk losing its rights under the Lucent Agreement.  Although the funding is an obligation of SenseIt, we have a right of first refusal to provide SenseIt the necessary funding by purchasing additional shares of SenseIt Series A Common Stock at $10 per share.  We believe that our interest in SenseIt could be significantly diluted were SenseIt to seek funding from third parties at this stage.  Also under the Lucent Agreement, SenseIt has the right to terminate the development project for any reason from time-to-time, so long as termination is prior to the first commercial sale of a licensed product.  As such, assuming (without assurance) SenseIt continues with the development program, we expect our quarterly research and development expense for this purpose to remain elevated.  If we are unable to provide SenseIt with the funds necessary to make the quarterly Lucent payments due to Lucent, SenseIt will be required to seek funding from outside sources.

24




We believe that the development and introduction of new product applications is critical to our future success, but we are unable to continue any significant research and development efforts given our current working capital shortages.  If we expend any funds for research and development, we are unlikely to expend those funds on our IMS-based products.  However (assuming we are able to raise sufficient funds and Lucent chooses to restart the project (which cannot be assured), we expect that research and development expenses would increase at SenseIt.  It is likely that research and development expenditures will continue to vary as a percentage of revenues because of the timing and amount of future revenues and the timing of and availability of working capital for research and development expenses. Except for work being performed on our semiconductor products at our facilities in Vancouver, Washington, we operate no other facilities of our own for research and development.  Significantly all other research and development work is performed by outside entities, none of which we control.  Although we expend significant resources on research and development, we cannot offer any assurance that our current or future lines of business or products resulting from our research and development efforts will be profitable or generate significant revenues.

Operating (Loss) Income

For the three months ended July 31, 2007 and 2006, our operating segments incurred operating (loss) income as follows:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Homeland security products

 

$

(1,321,000

)

$

(1,114,000

)

Security services

 

70,000

 

(274,000

)

Semiconductor products and services

 

(361,000

)

(199,000

)

Reconciling amounts (1)

 

(624,000

)

(2,366,000

)

Total

 

$

(2,236,000

)

$

(3,953,000

)

 


(1) Reconciling amounts for the operating loss information includes corporate expenses consisting primarily of corporate salaries and benefits, professional and consulting fees, investor relations costs, insurance and directors’ compensation. In January 2007, we elected to discontinue the operation of our life sciences business and put the assets and business up for sale (which was sold in June 2007).  As a result, we reclassified the operations of our life sciences business as discontinued operations.  Prior year information has been reclassified to conform with the current year presentation.

Our homeland security products segment has generated significant operating losses as our effort to develop and commercialize our IMS technology has not been successful.  As a result of the suspension of the development, manufacture and sale of our IMS-based products as described above, we expect that future operating losses will decrease as we seek alternatives towards finding a means of monetizing our IMS-based investment, including the development of a strategic partnership or an outright sale of the technology.  It is unclear as to when (if at all) we will resume activity on our IMS-based products and we can offer no assurance that we will be able to monetize any portion of our IMS-based investment.

For the three months ended July 31, 2007 and 2006, our security services segment delivered revenue of $3,756,000 and $3,877,000, respectively.  The operating income for the three months ended July 31, 2007, is due primarily to the benefits received from the cost cutting initiatives we implemented at PPSC during the six months ended July 31, 2007 (see below for additional discussion).  The operating loss for the three months ended July 31, 2006 is inclusive of a write-off of a single customer’s accounts receivable balance in the amount of $114,000.  Although we continue to pursue selected domestic government contracts, we have taken steps to reduce our spending on sales and marketing in this area.

During the six months ended July 31, 2007, we implemented significant cost cutting initiatives that are expected to positively impact the results of PPSC’s operations.  Additionally we initiated plans to improve operating margins at PPSC by focusing on customers that are willing to pay for premium security services, where PPSC is able to differentiate itself from its

25




peers.  As a result, we have and will continue to exit lower-margin business areas in lieu of premium accounts that prefer higher quality of service.  While we believe that these cost cutting initiatives and refocused sales and marketing efforts will enable PPSC to report positive operating income for the year ending April 30, 2008, we can offer no assurance that this will actually occur.

Our semiconductor operations, based in Vancouver, Washington, showed continued operational and financial improvement during the years ended April 30, 2007 and 2006, although we have experienced a softening of demand for our products and services during the three months ended July 31, 2007 and subsequently (as discussed further below).  The segment generated operating income for the year ended April 30, 2007, in the amount of $326,000 (which includes a non-cash charge of $122,000 for stock-based compensation expense) as compared to an operating loss for the year ended April 30, 2006, in the amount of $(5,151,000).  The positive operating income results primarily from our ongoing effort to reduce our reliance on low margin small diameter products and diversify into higher margin 300-millimeter products and services, wafer thinning and custom wafer products.

The large-diameter wafer segment has become one of the fastest growing segments of the silicon wafer market and the revenues and gross margins associated with the services are greater than those associated with the small diameter market.   As a result of our strategic realignment, revenue from 300-millimeter services comprised approximately 46% of segment revenue for the three months ended July 31, 2007 ($970,000 of revenue) and 54% of segment revenue for the year ended April 30, 2007 ($7,049,000 of revenue), as compared to approximately 36% of segment revenue for the year ended April 30, 2006 ($2,053,000 of revenue).  At the same time, there has also been a focus on operational efficiency and effectiveness, which has resulted in increased productivity and processing yields.  Further, we continue to gain new customers and are also in the process of attempting to qualify our product at others.

While we reported significant revenue and operating income growth in our semiconductor operations for the year ended April 30, 2007, many of our top semiconductor customers experienced weakened business results in recent quarters.  In addition, some customers have reported inventory buildup in reclaim and/or test products.  As a result of these two factors, we have recently seen a slowdown in orders of reclaim and test materials, which has had a negative impact on our operations.

The slowdown significantly impacted our results of operations and cash flows for the three months ended July 31, 2007 in which we generated an operating loss of $(361,000) as compared to $(199,000) for the three months ended July 31, 2006.  The impact of the slowdown in orders on our business is magnified when the results are compared to the three months ended April 30, 2007 whereby we generated operating income of $286,000.

In order to minimize the effect of the slowdown, we have implemented many cost cutting measures and will continue to do so.  It is unclear as to when our customers’ demand will rebound but we believe that this is a relatively short-term condition and are hopeful that we will begin to see a recovery during the next six months.  While we continue to aggressively pursue and add new customers to mitigate the underlying uncertainties with our existing customer base, we expect to reflect a significant reduction in revenue for the three months ended October 31, 2007 (as compared to the three months ended October 31, 2006) and the reporting of an operating loss for that segment.  We continue to monitor the situation closely and while we believe that we will see improving financial results in this operating segment (over the long-term), we cannot offer any assurance that we will be able to regain or sustain operating profitability in future periods.

Other Income (Expense), net

Other income (expense), net decreased for the three months ended July 31, 2007 and 2006 as both a dollar amount and as a percentage of revenues, as reflected in the following table:

26




 

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

(1,402,000

)

$

1,545,000

 

Percent of revenues

 

(23.9

)%

22.7

%

 

For the three months ended July 31, 2007, other income (expense), net consists of interest expense of $(1,429,000), the amortization of debt issuance costs of $(41,000) and equity in the net loss of an investee of $(42,000) partially offset by interest and other income of $97,000 and a gain on derivative instruments of $13,000.  Included in interest expense for the three months ended July 31, 2007 are non-cash charges of $1,335,000 related primarily to the amortization of the discount and the accrual of interest on our outstanding convertible debentures.

For the three months ended July 31, 2006, other income (expense), net consists of the recording of a gain on derivative instruments in the amount of $2,131,000 related to the change in fair value of the two derivative liabilities which we recorded in our condensed consolidated balance sheets and the recording of a gain on extinguishment of debt in the amount of $227,000, which resulted from the retirement of $3,880,000 in principal amount of 8% Debentures partially offset by $(650,000) of interest expense, $(115,000) of amortization of debt issuance costs and equity in the net loss of an investee of $(88,000).

We expect that our other expenses will be volatile based on the future timing of repayment , if ever, of the remaining convertible debentures (see the Liquidity and Capital Resources discussion below) and the fluctuations in fair value of and classification of the instruments underlying our derivative liabilities.

Income Taxes

We currently operate at a loss and expect to operate at a loss until (if ever) our operations begin to generate sufficient revenue. The losses incurred in the current year are not expected to generate an income tax benefit because of the uncertainty of the realization of the deferred tax asset. As a result, we have provided a valuation allowance against our net deferred tax asset because, based on available evidence including our continued operating losses, it is more likely than not that all of the deferred tax assets will not be realized. Additionally, due to certain “change in ownership” rules (as defined by the IRS), utilization of our federal net operating losses may be subject to certain annual limitations.

Minority Interest in Operations of Consolidated Subsidiary

Minority interest in operations of consolidated subsidiary for the three months ended July 31, 2007 and 2006 is reflected in the following table:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

100,000

 

 

Percent of revenues

 

1.7

%

 

 

The amount of minority interest in operations of consolidated subsidiary recorded for the three months ended July 31, 2007, relates to our purchase of a 90% interest in SenseIt in October 2006 and the subsequent operation of the business.  The amount is expected to fluctuate in future periods dependent upon the development and, potentially, financing activities of SenseIt in future reporting periods.  As indicated above, we do not have the capital necessary to make further investments in SenseIt and, as a result, SenseIt may lose its only business opportunity – participation in the Lucent Agreement.

27




Gain on Discontinued Operations, net of Income Taxes

Gain on discontinued operations, net of income taxes increased on both a dollar and a percentage of revenues basis for the three months ended July 31, 2007, as compared to the same period of our prior fiscal year as reflected in the following table:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

553,000

 

$

36,000

 

Percent of revenues

 

9.4

%

0.5

%

 

In January 2007, we decided to discontinue the operation of our life sciences business and to put the assets and business up for sale (which was sold in June 2007).  We decided to sell this business as it no longer fit our long-term strategy and because of deteriorating business conditions in the historical, revenue producing products in the segment.  Accounting rules required us to treat the operations of the life sciences business as discontinued operations whereby the net financial impact of the operations of the business is combined into a single line item and prior periods are reclassified for this presentation.  The gain, net of income taxes, resulting from operations of the life sciences business was $37,000 and $36,000 for the three months ended July 31, 2007 and 2006, respectively.  The gain on sale of the life sciences business was recorded in the three months ended July 31, 2007, in the amount of $516,000.  Revenue for the life sciences business, reported in the single line item of gain on operations of discontinued operations, net of income taxes, was $101,000 and $616,000 for the three months ended July 31, 2007 and 2006, respectively.

Net Loss

Net loss for the three months ended July 31, 2007 and 2006 is reflected in the following table:

 

Three months ended July 31,

 

 

 

2007

 

2006

 

Dollar amount

 

$

(2,985,000

)

$

(2,372,000

)

Percent of revenues

 

(50.9

)%

(35.0

)%

 

We anticipate that consolidated losses will continue until (if ever): (i) revenues from our current operations substantially increase or (ii) we generate substantial revenues from products introduced as a result of our research and development projects.  Further, the revenue increases must increase faster than any increases in operating and research and development expenses.  Additionally, we expect that our consolidated net loss will continue as we continue to work through the downturn in the semiconductor market.  As noted above, we have suspended development and marketing of our IMS-based products and Lucent has advised us that it intends to suspend operation under its agreement with SenseIt.  Therefore, we can offer no assurance that we will be able to proceed with either of these projects or that the development and commercialization of these technologies will ever occur.

We anticipate that our operations during the remainder of fiscal year 2008 will result in a loss since we are not likely to increase our revenues from our existing products or generate additional sales from the new products we may develop in a sufficient amount (if at all) to offset our operating and research and development expenses.

Liquidity and Capital Resources

Included in the following table are condensed consolidated balance sheet items as of July 31, 2007 and April 30, 2007 and condensed consolidated cash flow items for the three months ended July 31, 2007 and 2006:

28




 

 

As of

 

(in thousands)

 

July 31,
2007

 

Change

 

April 30,
2007

 

Cash and cash equivalents

 

$

1,482

 

$

(74

)

$

1,556

 

 

 

 

 

 

 

 

 

Working capital

 

$

1,953

 

(1,357

)

3,310

 

 

 

 

 

 

 

 

 

Current convertible debentures, net of discount

 

$

 

 

 

Convertible debentures, net of discount and current portion

 

9,374

 

740

 

8,634

 

Total convertible debentures, net of discount

 

$

9,374

 

$

740

 

$

8,634

 

 

 

 

 

 

 

 

 

Total convertible debentures, face value outstanding

 

$

18,000

 

$

 

$

18,000

 

 

 

Three months ended

 

 

 

July 31,
2007

 

Change

 

July 31,
2006

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

$

(453

)

$

2,989

 

$

(3,442

)

Net cash provided by (used in) investing activities

 

709

 

1,169

 

(460

)

Net cash (used in) provided by financing activities

 

(330

)

(8,063

)

7,733

 

Net (decrease) increase in cash and cash equivalents

 

$

(74

)

$

(3,905

)

$

3,831

 

 

Working Capital

Our working capital was $1,953,000 as of July 31, 2007, as compared to working capital of $3,310,000 as of April 30, 2007. This $1,357,000 decrease in working capital for the three months ended July 31, 2007, is due to a combination of factors, of which the significant factors are set out below:

Factors which increased working capital

·                  net cash of $805,000 received from the sale of our life sciences business in June 2007.

Factors which decreased working capital

·                  $1,433,000 of cash consumed directly in operating activities (calculated as $453,000 of cash used in operating activities, increased by $980,000 of the cash impact of net changes in other current assets or liabilities included therein);

·                  $96,000 related to purchases of fixed assets;

·                  $172,000 representing the current portion of capital lease entered into during the three months ended July 31, 2007;

·                  $90,000 in reclassification of capital leases from long-term to current;

·                  $344,000 of notes payable entered into during the three months ended July 31, 2007, in the normal course of business.

Based on the amount of capital we have remaining and our expected negative cash flow from operations and investing activities, we anticipate that we will not be able to positively impact our working capital unless we are able to substantially increase our revenues or

29




reduce our expenses thereby generating positive cash flow from operations and (ultimately) operating income.   We believe we have sufficient working capital to finance our anticipated operations and projected negative cash flow only into our quarter ending January 31, 2008, unless we are able to achieve significant additional financing.  Because of the potential dilution associated with the outstanding debentures and the holder’s security interest in substantially all of our assets, we believe that it is unlikely that we will be able to obtain additional financing unless we are able to reach an accommodation with our existing debenture holder.

Convertible Debentures

We currently have two series of convertible debentures outstanding, the 2006 Debentures and the April 2007 Debenture (together referred to as the “13% Debentures”).  Selected information regarding the 13% Debentures follows (dollars in thousands):

 

 

2006
Debentures

 

April 2007
Debenture

 

Total

 

Debenture agreement date(s)

 

May, June and
November
2006

 

April 2007

 

 

 

 

 

 

 

 

 

 

Due date - principal and interest

 

May 2009

 

May 2009

 

 

 

 

 

 

 

 

 

 

Interest rate

 

13

%

13

%

 

 

 

 

 

 

 

 

 

Outstanding balances as of July 31, 2007:

 

 

 

 

 

 

 

Face value

 

$

16,000

 

$

2,000

 

$

18,000

 

Accrued interest

 

1,375

 

80

 

1,455

 

Total liability

 

$

17,375

 

$

2,080

 

$

19,455

 

 

We are contractually required to obtain shareholder approval of the April 2007 Debenture (held by YA Global) by no later than November 30, 2007.  Due to a lack of working capital, we have decided to postpone our annual meeting of shareholders to a time subsequent to November 30, 2007.  If, as expected, we do not obtain shareholder approval of the April 2007 Debenture by November 30, 2007, and do not receive a waiver from the holder of the April 2007 Debenture, the holder of that debenture may declare an Event of Default.  Further, a default provision in the 2006 Debentures (also held by YA Global) would allow the holder to also declare an Event of Default of that debenture agreement if we were declared in default of the April 2007 Debenture.  Remedies for an Event of Default under all convertible debenture agreements include the option to accelerate payment of the full principal amount of the respective debenture, together with interest and other amounts due (a cumulative $19,455,000 as of July 31, 2007), to the date of acceleration and the holder will have the right to request such payment in cash or in shares of our common stock.  If the holder declares default, it is unlikely that we will be able to cure the default or contest any efforts that the holder may take to foreclose against its security interest in substantially all of our assets.

Cash Flows

As of July 31, 2007, we had $1,482,000 of cash and cash equivalents, a decrease of $74,000 as compared to $1,556,000 at April 30, 2007. Our principal source of funding for the three months ended July 31, 2007 was from the existing working capital as of April 30, 2007, along with the $805,000 (net of selling costs of $45,000) received for the sale of our life sciences business in June 2007.   Our principal source of funding for the three months ended July 31, 2006 was from the issuance of the 2006 Debentures (with a face amount of $13,000,000) for which we received net proceeds of $12,270,000.

30




Cash used in operating activities of $(453,000) and $(3,442,000) for the three months ended July 31, 2007 and 2006, respectively, was primarily the result of a net loss of $(2,985,000) (which included noncash expenses and gains in the net amount of a $(935,000) expense) and of $(2,372,000) (which included noncash expenses and gains in the net amount of a $725,000 gain), respectively.

Investing activities provided cash of $709,000 and used cash of $(460,000) for the three months ended July 31, 2007 and 2006, respectively. Cash provided by investing activities for the three months ended July 31, 2007, consisted of $805,000 (net of selling costs of $45,000) received for the sale of our life sciences business in June 2007 offset by $96,000 expended on additions of property and equipment.  Cash used in investing activities for the three months ended July 31, 2006, consisted of $360,000 expended on additions of property and equipment and $100,000 expended on a 9% equity investment in a business.

Financing activities used cash of $(330,000) and provided cash of $7,733,000 for the three months ended July 31, 2007 and 2006, respectively. Cash used in financing activities for the three months ended July 31, 2007, consisted of payments of principal on capital leases and notes payable in the amounts of $106,000 and $224,000, respectively.  Cash provided by financing activities for the three months ended July 31, 2006, resulted primarily from the issuance of the 6% Debentures, which yielded net proceeds of $12,270,000 offset primarily by principal payments on borrowings of $4,549,000.

Additional Liquidity Considerations

As of July 31, 2007, we have 1,992,377 common stock warrants exercisable at $5.00 related to the 8% Debenture transaction.  In May 2006, 1,139,250 of these common stock warrants were modified to reduce their anti-dilution provisions to a price-protection provision only. If we were to enter into a financing agreement in the future with an effective price less then $5.00 (or of the holder of our 13% Debentures was to convert a portion of any outstanding debenture at a conversion rate less than $5.00), the remaining 853,125 common stock warrants that have a full anti-dilution provision, would ratchet into a greater number of common stock warrants at a lower exercise price.

As of July 31, 2007, we had commitments outstanding for capital expenditures of approximately $100,000.  Although our commitment to continue to fund the development operations under the agreement between SenseIt and Lucent is not an obligation, it is our desire to continue to do so.  However, we do not currently have the capital to permit us to meet that commitment and, if Lucent terminates the development program, we will most likely lose our entire investment in SenseIt as it will become valueless.

We have satisfied our working capital requirements primarily through financing activities in the past, including the issuance of the 8% Debentures in February 2005 and the 13% Debentures in May, June and November 2006 and April 2007. During our year ended April 30, 2007, we cured several listing deficiencies with Nasdaq.   We expect to receive additional deficiency notifications in the near future, which, if not cured timely, will most likely result in our delisting from the Nasdaq Capital Market. Any such delisting, if it should occur, will make future financing activities significantly more difficult.

The assumptions underlying the above statements include, among other things, that there will be no material adverse developments in the business or market in general. There can be no assurances however that those assumed events will occur. If our plans are not achieved, there may be further negative effects on the results of operations and cash flows, which could have a material adverse effect on our financial position.

Off-Balance Sheet Arrangements

We have no material changes to the disclosure on this matter made in our Annual Report on Form 10-K for the year ended April 30, 2007.

31




Critical Accounting Estimates

We consider an accounting estimate to be critical if 1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and 2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

Management has discussed the development and selection of these critical accounting estimates with the Audit Committee of our Board of Directors and the Audit Committee has reviewed the foregoing disclosure.  In addition, there are other items within our financial statements that require estimation, but are not deemed critical as defined above.  Changes in estimates used in these and other items could have a material impact on our financial statements.

Goodwill and Intangible Assets

Goodwill is recorded on our books for acquisitions where the purchase price is in excess of the cumulative fair values of the identified tangible and intangible assets.  The assignment of fair value to the identified tangible and intangible assets requires significant judgment and may require independent valuations of certain identified assets.  Once goodwill and other intangible assets are established on our balance sheet, we evaluate the assets for impairment as described in the following paragraphs.

In accordance with SFAS No. 142 Goodwill and Other Intangible Assets, goodwill is not amortized, but instead is tested for impairment on an annual basis or more frequently if the presence of certain circumstances indicates that impairment may have occurred.  The impairment review process, which is subjective and requires significant judgment at many points during the analysis, compares the fair value of the reporting unit in which goodwill resides to its carrying value.  If the carrying value of a reporting unit exceeds its fair value, then the amount of the impairment loss must be measured. The impairment loss is calculated by comparing the implied fair value of reporting unit goodwill to its carrying amount. In calculating the implied fair value of reporting unit goodwill, the fair value of the reporting unit is allocated to all of the other assets and liabilities of that unit based on their fair values. The excess of the fair value of a reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. An impairment loss would be recognized when the carrying amount of goodwill exceeds its implied fair value. We have goodwill in the amount of $3,631,000 on our condensed consolidated balance sheet as of July 31, 2007, related to the acquisition of PPSC in May 2005.  During the three months ended January 31, 2007, we performed our annual impairment review on the aforementioned goodwill and concluded that the goodwill is not impaired.

For intangible assets other than goodwill, SFAS No. 144 Accounting for the Impairment or Disposal of Long-Lived Assets (“SFAS 144”) is the authoritative standard on the accounting for the impairment of such intangible assets.  As required, we perform tests for impairment of intangible assets other than goodwill whenever events or circumstances suggest that such assets may be impaired.  To evaluate potential impairment, SFAS No. 144 requires us to assess whether the future cash flows related to these assets will be greater than their carrying value at the time of the test. Accordingly, while our cash flow assumptions are consistent with the plans and estimates we are using to manage the underlying businesses, there is significant judgment in determining the cash flows attributable to our other intangible assets over their respective estimated useful lives.  We have remaining other net intangible assets in the amount of $259,000 on our condensed consolidated balance sheet as of July 31, 2007, comprised of our IMS detection technology acquired in December 2002 and the customer base acquired in our acquisition of PPSC in May 2005.  We are required to periodically evaluate our other intangible assets balances for impairments. If we were to incur additional impairments to our other intangible assets, it could have an adverse impact on our future earnings, if any.

32




Valuation of Equity Transactions

We value transactions associated with common or preferred stock that is convertible into common stock based on the market value of the underlying common stock on the date of the signing of the agreement (or, sometimes, at the date of conversion). We value transactions associated with common stock warrants at the appropriate measurement date utilizing at a minimum, the Black-Scholes pricing model, with assumptions as to volatility, risk-free interest rate and estimated life of the warrants based on historical information related to the life of the underlying warrant. If the assumptions used, as they relate to volatility, risk-free interest rate and estimated life of the warrants, were materially different, the overall valuation of these transactions could change significantly.

Valuation of Convertible Debenture Transactions

We enter into transactions that include debentures that are convertible into common stock at rates that may be fixed or variable and also include detachable common stock warrants.  We allocate the proceeds from the debenture transactions based on the estimated fair values of the debentures and the warrants.  If the assumptions used, as they relate to volatility, risk-free interest rate and estimated life of the warrants (including any anti-dilution adjustment provisions) and the fair value of the debentures (included the specific conversion features) were materially different, the overall allocation of proceeds for these transactions could change significantly.  Further, at times we have classified certain embedded conversion features or warrants issued in convertible debenture transactions as derivative liabilities in accordance with US GAAP.  The estimates of fair value of these derivative liabilities involve complex assumptions in the initial recording of the liabilities and in the mark-to-market required for each reporting period.  If the assumptions used to determine the fair value of these liabilities were materially different, the valuation of the liabilities could change significantly.

Stock-Based Compensation Expense

We account for stock-based compensation in accordance with SFAS 123(R).  Under the fair value recognition provisions of SFAS 123(R), stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense ratably over the requisite service period of the award.  Determining the appropriate fair value model and calculating the fair value of stock-based awards, which includes estimates of stock price volatility, forfeiture rates and expected lives, requires judgment that could materially impact our operating results.

Item 3: Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk related to changes in interest rates, equity security market values, foreign currency rates and the market price of our common stock.

Interest Rates

Our investment portfolio consists of cash and cash equivalents (in the amount of $1,482,000 as of July 31, 2007), all of which is exposed to interest rate fluctuations.  The primary objective of our investments is to earn a market rate of return while preserving principal and maximizing liquidity.  The interest earned on these investments (with a blended yield of 0.5% at July 31, 2007) may vary based on fluctuations in the prevailing interest rate.

Equity Securities

We do not hold any investments in marketable equity securities.  However, we hold interests in various wholly- and partially-owned subsidiaries.  These securities are non-marketable.  Our investment in these subsidiaries may be impacted by the underlying economic conditions of the entity, including the ability to raise additional capital and the likelihood of our being able to realize our investments through liquidity events such as initial public offerings, mergers or

33




private sales.  These investments involve a great deal of market risk, and there can be no assurance that a specific company will grow or become successful.  Consequently, we could lose all or part of our investment.  Additionally, because IUT is located in Germany, our investment in the entity (and our share of their earnings or losses) may be impacted by changes in foreign currency rates.  The carrying amount of this investment is $340,000 as of July 31, 2007.

Derivative Instruments

We do not purchase derivative instruments on the open market.  However, in accordance with current US GAAP, we have classified certain warrants as derivative instruments (a $1,008,000 current liability at July 31, 2007).  Classification as derivative liabilities was required because there is a possibility that the instruments could be required to be settled on a net cash basis.  We are required to mark these instruments to market as of the end of each reporting period and to recognize the change in fair value in our condensed consolidated statements of operations.  Our stock price has been historically volatile and the fair values of these instruments are sensitive to changes in our underlying stock price.  As such, the carrying amount of these instruments may be volatile from period to period.  For the three months ended July 31, 2007, we recorded a gain on derivative instruments in the aggregate amount of $13,000 such amount representing the change in fair value between April 30, 2007, and July 31, 2007.  See Note 9 to the consolidated financial statements located in Item 8. “Financial Statements and Supplementary Data” of our Form 10-K for the year ended April 30, 2007, for a more detailed discussion of the derivative instruments.

Item 4: Controls and Procedures

Our management, with the participation of our principal executive officer and our principal financial officer have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of July 31, 2007 (the end of the period covered by this report). Based on that evaluation, our principal executive officer and our principal financial officer have concluded that these disclosure controls and procedures are effective as of such date.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting during the three months ended July 31, 2007, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II: Other Information

Item 1:  Legal Proceedings

None.

Item 1A: Risk Factors

In addition to the other information set forth in this report, you should carefully consider the following factors, which could materially affect our business, financial condition or future results.  The risks described below are not the only risks we face. 

34




Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or results of operations.

We have historically had working capital shortages, even following significant financing transactions and we received an opinion from our auditors indicating a substantial doubt regarding our ability to continue as a going concern.

We have had working capital shortages in the past and, although we raised capital totaling more than $45,800,000 (net of expenses and $4,100,000 of payments related to our 8% Debentures) since May 1, 2004, we have generated significant losses, which have impacted working capital.  As of July 31, 2007, our condensed consolidated balance sheet reflects working capital of $1,953,000.  In addition, as a result of our continued operating losses and projected declining working capital balances during the year ending April 30, 2008, the auditors report included with our financial statements for the year ended April 30, 2007 included an explanatory paragraph indicating substantial doubt about our ability to continue as a going concern.

Based on the amount of capital we have remaining and our expected negative cash flow from operations and investing activities, we anticipate that we will not be able to positively impact our working capital unless we are able to substantially increase our revenues or reduce our expenses thereby generating positive cash flow from operations and (ultimately) operating income.  We believe we have sufficient working capital to finance our anticipated operations and projected negative cash flow only into our quarter ending January 31, 2008, unless we are able to achieve significant additional financing.  Because of the potential dilution associated with the outstanding debentures and the holder’s security interest in substantially all of our assets, we believe that it is unlikely that we will be able to obtain additional financing unless we are able to reach an accommodation with our existing debenture holder.

We are contractually required to obtain shareholder approval of the April 2007 Debenture (held by YA Global) by no later than November 30, 2007.  Due to a lack of working capital, we have decided to postpone our annual meeting of shareholders to a time subsequent to November 30, 2007.  If, as expected, we do not obtain shareholder approval of the April 2007 Debenture by November 30, 2007, and do not receive a waiver from the holder of the April 2007 Debenture, the holder of that debenture may declare an Event of Default.  Further, a default provision in the 2006 Debentures (also held by YA Global) would allow the holder to also declare an Event of Default of that debenture agreement if we were declared in default of the April 2007 Debenture.  Remedies for an Event of Default under all convertible debenture agreements include the option to accelerate payment of the full principal amount of the respective debenture, together with interest and other amounts due (a cumulative $19,455,000 as of July 31, 2007), to the date of acceleration and the holder will have the right to request such payment in cash or in shares of our common stock.  If the holder declares default, it is unlikely that we will be able to cure the default or contest any efforts that the holder may take to foreclose against its security interest in substantially all of our assets.

Our ability to obtain further necessary financing is limited.

We have historically financed our operating losses and cash flow deficits through private placements of our equity and debt securities.  Our outstanding 13% Debentures contain significant restrictions on our ability to raise any additional capital for so long as the convertible debentures are outstanding.  While ultimately our ability to finance our operations will depend on our ability to generate revenues that exceed our expenses, we have short-term needs for significant additional financing which may not be available because of the outstanding debentures, as well as the significant number of outstanding options and warrants which contain adjustment provisions should we issue shares of our common stock at prices below the current exercise prices.  We do not believe that we will be able to obtain additional financing without the cooperation of our principal debenture holder.  Although we have had numerous discussions with our principal debenture holder, we cannot offer any assurance that it will take the steps necessary for us to obtain the financing we need to continue our business operations through the

35




current fiscal year.  Ultimately our only source of additional capital may be the holder of our outstanding debentures, and if that holder declines (for any reason) to invest additional amounts into Isonics, we may not be able to continue as a going concern.

We may be delisted from the Nasdaq Capital Market and delisting may adversely impact our ability to raise capital.

Although our common stock is quoted on the Nasdaq Capital Market, at July 31, 2007 our stockholders’ equity was $766,000 and thus we have failed to meet the listing requirement of either stockholders’ equity of at least $2,500,000 or market value of listed securities of at least $35,000,000.  As a result, upon filing this Form 10-Q we expect to receive a notice from Nasdaq for failure to comply with this requirement.  In addition, our per-share bid price is (and has been for some time) below the required $1.00 minimum requirement and as a result we expect to receive a notice from Nasdaq for failure to comply with this requirement as well.  Given our current lack of working capital, ongoing operating losses and difficulty in obtaining additional financing it is likely that we will not be able to cure these deficiencies.  If we are not able to cure such deficiencies, it most likely will result in our delisting from the Nasdaq Capital Market.

Because our financing activities are dependent to a large extent on eventual liquidity for the investors, any such delisting, if it should occur, will make future financing activities significantly more difficult, may raise liquidity issues for current investors and may place some of our existing obligations into default.

We have three business segments and, for the three months ended July 31, 2007, two of our three segments operated at a loss.

For the three months ended July 31, 2007 and 2006, our operating segments incurred operating (loss) income as follows:

 

For the three months ended July 31,

 

 

 

2007

 

2006

 

Homeland security products

 

$

(1,321,000

)

$

(1,114,000

)

Security services

 

70,000

 

(274,000

)

Semiconductor products and services

 

(361,000

)

(199,000

)

Reconciling amounts (1)

 

(624,000

)

(2,366,000

)

Total

 

$

(2,236,000

)

$

(3,953,000

)

 


(1) Reconciling amounts for the operating loss information includes corporate expenses consisting primarily of corporate salaries and benefits, professional and consulting fees, investor relations costs, insurance and directors’ compensation. In January 2007, we elected to discontinue the operation of our life sciences business and put the assets and business up for sale (which was sold in June 2007).  As a result, we reclassified the operations of our life sciences business as discontinued operations.  Prior year information has been reclassified to conform with the current year presentation.

We expect that these losses (on a consolidated basis) will continue for the foreseeable future.  As described in the next risk factor, unless we are able to develop and sell new products profitably, we may be unable to remain competitive and it is likely that our losses and negative cash flow will continue.

Unless we are able to develop and sell our products profitably, we may be unable to remain competitive, furthering the likelihood that our losses and negative cash flow will continue.

Our ability to generate positive cash flow, additional revenues, and ultimately net income, is dependent upon the success of our homeland security products, security services and semiconductor operations.  We have discontinued development of our IMS-based products.

36




While we reported significant revenue and operating income growth in our semiconductor operations for the year ended April 30, 2007, many of our top semiconductor customers experienced weakened business results in recent quarters.  In addition, some customers have reported inventory buildup in reclaim and/or test products.  As a result of these two factors, we have recently seen a slowdown in orders of reclaim and test materials, which has had a negative impact on our operations.

The slowdown significantly impacted our results of operations and cash flows for the three months ended July 31, 2007, in which we generated an operating loss of $(361,000) as compared to $(199,000) for the three months ended July 31, 2006.  The impact of the slowdown in orders on our business is magnified when the results are compared to the three months ended April 30, 2007, whereby we generated operating income of $286,000.

In order to minimize the effect of the slowdown, we have implemented many cost cutting measures and will continue to do so.  It is unclear as to when our customers’ demand will rebound but we believe that this is a relatively short-term condition and are hopeful that we will begin to see a recovery during the next six months.  While we continue to aggressively pursue and add new customers to mitigate the underlying uncertainties with our existing customer base, we expect to reflect a significant reduction in revenue for the three months ended October 31, 2007 (as compared to the three months ended October 31, 2006) and the reporting of an operating loss for that segment.  We continue to monitor the situation closely and while we believe that we will see improving financial results in this operating segment (over the long-term), we cannot offer any assurance that we will be able to regain or sustain operating profitability in future periods.

We have had limited success in marketing our homeland security products, having sold to date only fifteen units of our panel-mounted IMS-based product.  In August 2007, we elected to suspend the development, manufacture and sale of our IMS-based products.  The suspension was due primarily to a lack of working capital but we have also had difficulty competing in the market space.  We will continue to seek alternatives towards finding a means of monetizing our IMS-based investment, including the development of a strategic partnership or an outright sale of the technology.  It is unclear as to when (if at all) we will resume activity on our IMS-based products and we can offer no assurance that we will be able to monetize any portion of our IMS-based investment.

We have issued securities during the years ended April 30, 2007, 2006 and 2005, and subsequently which has resulted (and will in the future when warrant exercises or conversions occur) in dilution to our existing shareholders.  This was accomplished to provide necessary working capital or obtain assets and services.  We will likely issue more securities to raise additional capital or to obtain other services or assets, any of which may result in substantial additional dilution.

During the course of the last three fiscal years, we have raised in excess of $45,800,000 (net of expenses and $4,100,000 of payments related to our 8% Debentures) to finance our business operations and acquisitions. During that period and subsequently, we have also issued a number of shares, options, and warrants, to acquire services and assets from third parties and pursuant to our stock option plans.  If possible under terms that we believe to be appropriate given our financial condition and other circumstances (including our existing capital structure), we intend to raise additional financing during our year ending April 30, 2008.  We also expect to issue additional shares, options, and warrants where we can to obtain necessary services.  Some of the issuances we have made in the past and are likely to make in the future have been issued at prices below market and (as is frequently the case with declining market prices) at prices below our historical market prices.  Consequently, our shareholders have suffered dilution in the value of their shares and can expect that we will be issuing additional securities on similar terms.  Further dilution can be expected to occur when our outstanding options and warrants are exercised or debentures are converted at prices below the market.

Two former holders of a portion of the then outstanding 8% Debentures have asserted that a default existed.

37




Two entities who held 8% Debentures (which were paid in full as of February 1, 2007) have previously asserted that the issuance of the 13% Debentures constituted a default (due to a potential variable conversion provision contained within the 13% Debentures which gives the 13% Debenture holder the right to convert the 13% Debentures into common stock at the lower of $5.00 or at a discount to market, subject to certain limitations and as defined) under the 8% Debentures.  We have contested that allegation (based on such clause not surviving the final agreement and a defense of in pari delicto), and will defend it in court if necessary.  Although we have not had any further communication from the former holders regarding this issue other than the allegation of default, any litigation would be time consuming and expensive and, although we believe that we have significant grounds to contest the existence of any default, we cannot be assured of success.  If they were to prove a default, we could be liable for 130% of the principal amount of their 8% Debentures on the closing date of the 13% Debenture transaction (an amount of approximately $1,200,000, including accrued interest).

Accounting charges resulting from our issuance of the 13% Debentures may lead to significant non-cash charges which would adversely impact future interest expense, net income and earnings per share and may also lead to future volatility in our financial statement components.

As a result of the issuance of the 13% Debentures, we will be required to record significant non-cash interest charges over the life of the 13% Debentures (in addition to interest expense relating to the 13% interest rate borne by the 13% Debentures which will be paid in cash or shares of our common stock, at our option).  This will likely result in a significant adverse impact to future net income and earnings per share and will likely introduce additional volatility to our future operating results.

Historically we depended upon few customers for a significant portion of our revenues and our business could have been materially and adversely affected if we lost any one of those customers.

We have been dependent on a few significant customers who have purchased our products or services in amounts greater than 10% of our consolidated revenues.  A decision by any significant customer to substantially decrease or delay purchases from us or an inability to collect significant amounts owed to us could have a material adverse effect on our consolidated financial condition and results of operations.

We realized increased expenses, reduced revenues and longer than anticipated delays in integrating past business acquisitions into our operations, and we may face similar difficulties with future acquisitions as well.

We experienced increased costs and delays in integrating the operations of the business and assets we acquired from EnCompass Materials Group, Ltd. (“EMG”) in June 2004, and we also realized revenues that were significantly reduced from that which we had anticipated which adversely affected the operations of our semiconductor division.  Regardless of the extent of our planning, we may recognize increased costs and delays, and reduced revenues, when integrating future business acquisitions into our business operations and strategy.  While we believe that we have and will continue to plan for integration of acquired business operations to the best of our ability, we cannot offer any assurance that any or all such efforts will proceed as anticipated.

If demand for any of our products grows suddenly, we may lack the resources to meet demand or we may be required to increase our capital spending significantly.

If we are able to develop and market our products successfully, we may experience periods of rapid growth that place a significant strain on our financial and managerial resources.  Through our research and development efforts we are also attempting to develop additional products and lines of business.  Our ability to manage growth effectively, particularly given our increasing scope of operations, will require us to continue to implement and improve our

38




management, operational and financial information systems, and will require us to develop the management skills of our personnel and to train, motivate and manage our employees.  Our failure to effectively manage growth could increase our costs of operations and reduce our margins and liquidity, which could have a material adverse effect on our business, financial condition and results of operations.

Because we are dependent upon our key personnel for our future success, if we fail to retain or attract key personnel, our business will be adversely affected.

Our future success will depend in significant part upon the continued service of our key technical, sales and senior management personnel and consultants, including Christopher Toffales, our Chairman of the Board. Currently Mr. Toffales is covered by a two-year employment agreement that is renewable on an annual basis.  We believe that our future success will also depend upon our ability to attract and retain other qualified personnel for our operations.  The failure to attract or retain such persons could materially adversely affect our business, financial condition and results of operations.

We may not be able to protect our intellectual property, which would reduce our competitive advantage.

We rely primarily on a combination of patents and patent applications, trade secrets, confidentiality procedures, and contractual provisions to protect our technology.  Despite our efforts to protect our technology, unauthorized parties may attempt to copy aspects of our products or to obtain and use information that we regard as proprietary.  Policing unauthorized use of our technology and products is difficult.  In addition, the laws of many countries do not protect our rights to information, materials and intellectual property that we regard as proprietary and that are protected under the laws of the United States.  We may not be able to protect our proprietary interests, or our competitors may independently develop similar technology or intellectual property.  If either one of these situations occurs, we may lose existing customers and our business may suffer.

The validity of any of the patents licensed to us, or that may in the future be owned by us, may not be upheld if challenged by others in litigation.  Further, our products or technologies, even if covered by our patents, may infringe upon patents owned by others.  We could incur substantial costs in defending suits brought against us, or any of our licensors, for infringement, in suits by us against others for infringement, or in suits contesting the validity of a patent.  Any such proceeding may be protracted.  In any suit contesting the validity of a patent, the patent being contested would be entitled to a presumption of validity and the contesting party would be required to demonstrate invalidity of such patent by clear and convincing evidence.  If the outcome of any such litigation were adverse to our interests, our liquidity and business operations would be materially and adversely affected.

We face technological change and intense competition both domestically and internationally which may adversely affect our ability to sell our products profitably.

The markets for our homeland security and semiconductor products and services are characterized by rapidly evolving technology and a continuing process of development. Our future success will depend upon our ability to develop and market products that meet changing customer and technological needs on a cost effective and timely basis.  If we fail to remain competitive by anticipating the needs of our customers and our customers contract with other suppliers, our revenues and resulting cash flow could be materially and adversely affected.

Our semiconductor products and services segment is dependent on the performance of several key pieces of equipment.  If any of these items were not to perform to their ability or were taken out of service for any significant amount of time, our ability to produce product would be severely compromised.

39




The performance of our semiconductor products and services segment is directly tied to the performance of several key pieces of equipment, which are typically intricate and expensive.  The average time between failures is typically long and the corresponding time for repair is typically short; as a result, most of the time the issues are routine and are quickly repaired. However, this is not always the case and there have been times in the past when critical tools have been out of service for a period of time, which had a negative impact on revenues in the short term.  Further, due to our historical working capital shortages and the significant historical net losses, we are unable to purchase the necessary equipment redundancy.  Any future equipment issues could have a significant impact on our ability to produce and ship the products to our customers, thereby potentially impacting both our revenues and related cash flows.

We could be subject to environmental regulation by federal, state and local agencies, including laws that impose liability without fault, which could produce working capital shortages and lessen stockholders’ equity.

Our IMS-based products use radioactive sources.  As a result, we are subject to a variety of federal, state, and local environmental regulations relating to the use, storage, discharge and disposal of hazardous chemicals used during manufacturing processes.  Regulations that become applicable to our operations in the future could restrict our ability to expand our facilities or could require us to acquire costly equipment or to incur other significant expenses to comply with governmental regulations.  Historically, our costs of compliance with environmental regulations have not been significant because we use licensed manufacturers in connection with the manufacture of these products.

We are controlled by our Board of Directors; individual purchasers of our shares will have little ability to elect directors or control our management.

Our shares are widely-held, and our management beneficially owns our securities in an amount less than 10% of the outstanding votes at any shareholders’ meeting.  Nevertheless, it is likely that the Board of Directors will be able to influence all matters submitted to stockholders for approval, including the election and removal of directors and any merger, consolidation or sale of substantially all of our assets, and to control our management and affairs.  Such control may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation or takeover or other business combination involving us or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would be beneficial to other stockholders.

We risk exposing ourselves to an above-policy limit product liability claim, which could adversely affect our working capital, shareholders’ equity and profitability.

The sale and use of explosive and chemical detection products may expose us to potential liability risks that are inherent with the operation of these types of products (including, but not limited to failed detection).  We currently have product liability insurance; however, there is a risk that our insurance would not cover completely or would fail to cover a claim, in which case we may not have the financial resources to satisfy such claims, and the payment of claims would require us to use funds that are otherwise needed to conduct our business and make our products.

Our common stock is vulnerable to pricing and purchasing actions that are beyond our control and, therefore, persons acquiring or holding our shares or warrants may be unable to resell their shares at a profit as a result of this volatility.

The trading price of our securities has been subject to wide fluctuations in response to quarter-to-quarter variations in our operating results, our announcements of technological innovations or new products by us or our competitors, delays in our product development and marketing, and other events and factors over which we have no influence or control. The securities markets themselves have experienced significant price and volume fluctuations that may be unrelated

40




to the operating performance of particular companies. Regulatory developments in the United States and foreign countries, public concern as to the safety of products containing radioactive compounds, economic and other external factors, all affect the market price of our securities. In addition, the realization of any of the risks described in these “Risk Factors” could have a significant and adverse impact on such market prices.

SEC penny stock regulations may limit the ability to trade our securities.

Although our common stock is currently quoted on the Nasdaq Capital Market, our common stock has in the past been (and may, if delisted by Nasdaq again be) subject to additional disclosure requirements for penny stocks mandated by the Securities Enforcement Remedies and Penny Stock Reform Act of 1990.  The SEC Regulations generally define a penny stock to be an equity security that is not traded on the Nasdaq Stock Market and has a market price of less than $5.00 per share. We have, at times in the past, been included within the SEC Rule 3a-51 definition of a penny stock. When our common stock is considered to be a “penny stock,” trading is covered by Rule 15g-9 promulgated under the Securities Exchange Act of 1934, for non-Nasdaq and non-national securities exchange listed securities, adding a significant amount of broker-dealer compliance to transactions in penny stocks.  Many brokers are unwilling to engage in transactions in penny stocks and, therefore, if we lose our listing on the Nasdaq Capital Market, the marketability of our securities may weaken significantly.

We cannot give any assurance that we will be able to meet the Nasdaq requirements to maintain our Capital Market listing, or that if we do, a stable trading market will develop for our stock or our warrants. See “We may be delisted from the Nasdaq Capital Market and delisting may adversely impact our ability to raise capital” for additional risk factors associated with potential Nasdaq listing deficiencies.

Future sales of our common stock may cause our stock price to decline.

Our stock price has declined from a price of approximately $24.00 (adjusted for the reverse split) per share at the beginning of 2005 to prices of less than $0.55 (adjusted for the reverse split) at various times since May 2006. Our stock price may decline further as a result of future sales of our shares, the perception that such sales may occur, our financial or operational performance, or other reasons.  As of September 12, 2007, approximately 900,000 shares of common stock held by existing stockholders constitute “restricted shares” as defined in Rule 144 under the Securities Act.  The restricted shares may only be sold if they are registered under the Securities Act, or sold under Rule 144, or another exemption from registration under the Securities Act.

Approximately 90% of the restricted shares of our common stock are either eligible for sale pursuant to Rule 144 or have been registered under the Securities Act for resale by the holders.  We are unable to estimate the amount, timing, or nature of future sales of outstanding common stock.  Sales of substantial amounts of our common stock in the public market may cause the stock’s market price to decline.

We have never paid any cash dividends on our common stock and we do not anticipate paying cash dividends on our common stock in the foreseeable future.

We have never declared or paid a cash dividend on our common stock.  We presently intend to retain our earnings, if any, to fund development and growth of our business and, therefore, we do not anticipate paying cash dividends in the foreseeable future.  Additionally, the terms of the 13% Debentures contain restrictions on our ability to pay dividends to holders of our common stock.

If we fail to effect and maintain registration of the common stock issued or issuable pursuant to conversion of our convertible debentures, or certain of our outstanding common stock warrants, we

41




may be obligated to pay the investors of those securities liquidated damages.

We have various obligations to file and obtain the effectiveness of certain registration statements which include certain outstanding common stock and common stock underlying outstanding convertible debentures and common stock warrants.  Once effective, the prospectus contained within a registration statement can only be used for a period of time as specified by statute without there being a post-effective amendment filed that has become effective under the Securities Act of 1933.  If we are unable to meet these obligations, we may be obligated to pay liquidated damages of 1% of the principal amount of the 13% Debentures outstanding per month (up to $180,000 per month).  We cannot offer any assurance that we will be able to maintain the currency of the information contained in a prospectus or to obtain the effectiveness of any registration statement or post-effective amendments that we may file.

As a public company, we are subject to a significant amount of regulation.  In the past we have received requests for information from the Securities and Exchange Commission and from Nasdaq.  Any such inquiry or investigation that may result may adversely affect the market for our stock or our Company.

Regulators of public companies such as Isonics have the authority to commence inquiries and investigations where the regulators have concerns.  The investigations, while involving the company, may not have anything to do with actions taken by the company or our failure to act.  Furthermore, the regulators may not inform us when the issues they were addressing are resolved.  From October 2004 through February 2005, both Nasdaq and the SEC requested documents from us with respect to inquiries they were undertaking (related primarily to questions regarding our press releases, public relations advisors, certain other disclosures that were made publicly and the termination of Grant Thornton LLP as our independent auditor).   We also met with representatives of Nasdaq to discuss issues related to market activity, press announcements, SEC filings, status of our business and other issues.   We provided information, which we believe to be responsive to all of the questions posed in the Nasdaq inquiry and to the SEC.  We have not received any requests for additional information from either the SEC or Nasdaq relating to those earlier inquiries since February 2005 and while we believe these issues are behind us, if any action resulted from these inquiries in the future, it may adversely impact us, and our ability to carry on our business.

We failed to provide necessary funding to SenseIt to make the most recent development payment to Lucent and, as a result, Lucent could terminate the agreement and our investment in SenseIt would be impaired.  Even if we are able to make the development payment we have missed or future development payments when due, there is no guarantee that the development activity will yield technologically relevant and commercially viable products.

SenseIt failed to make the development payment due to Lucent on July 16, 2007.  SenseIt was unable to make this payment because we were unable to provide adequate funding to SenseIt.  Consequently, Lucent may in its discretion take steps to terminate the agreement and all licenses granted to us thereunder or cease working on the project and then assess SenseIt a “start-up” fee if funding was to resume.  On July 26, 2007, we received official notification from Lucent that we failed to make the $1,000,000 payment to Lucent by July 16, 2007, and that in the event such non-payment continues for more than ten days, Lucent may at is discretion, suspend work on or terminate the development project.  On September 7, 2007, we were notified by Lucent that if we fail to make the payment by September 16, 2007, Lucent intends to suspend work on the development project, although Lucent also has a right to terminate the agreement.  We will not be able to make such payment by September 16, 2007, due to insufficient working capital.  If Lucent were to terminate the project we will most likely lose our entire investment in SenseIt as it will become valueless.

Because of our continuing working capital shortages, we may not be able to provide SenseIt funding for current or future development payments to Lucent, and SenseIt may not be able to find third-party investors to provide it the necessary capital.  If the Lucent agreement were to be canceled, our investment in SenseIt would be impaired.  Lastly, although we are hopeful

42




of a positive outcome, we can offer no assurance that the development activity underway with Lucent and SenseIt will yield technologically relevant and commercially viable products.

Provisions in our charter documents could prevent or delay a change in control, which could delay or prevent a takeover.

Our Articles of Incorporation authorize the issuance of “blank check” preferred stock with such designations, rights, and preferences, as may be determined by our Board of Directors.  Accordingly, the Board of Directors may, without shareholder approval, issue shares of preferred stock with dividend, liquidation, conversion, voting, or other rights that could adversely affect the voting power or other rights of the holders of our common stock.  Preferred stock could also be issued to discourage, delay, or prevent a change in our control, although we do not currently intend to issue any additional series of our preferred stock.

Provisions in our bylaws provide for indemnification of officers and directors to the full extent permitted by California law, which could require us to direct funds away from our business and products.

Our Bylaws provide for indemnification of officers and directors to the full extent permitted by California law, our state of incorporation.  We may be required to pay judgments, fines, and expenses incurred by an officer or director, including reasonable attorneys’ fees, as a result of actions or proceedings in which such officers and directors are involved by reason of being or having been an officer or director. Funds paid in satisfaction of judgments, fines and expenses may be funds we need for the operation of our business and the development of our products, thereby affecting our ability to attain profitability.  This could cause our stock price to drop.

We will need to make substantial financial and man-power investments in order to assess our internal controls over financial reporting and our internal controls over financial reporting may be found to be deficient.

Section 404 of the Sarbanes-Oxley Act of 2002 requires management to assess our internal controls over financial reporting and requires auditors to attest to that assessment. Current regulations of the Securities and Exchange Commission, or SEC, require us to include this assessment and attestation in our Annual Report on Form 10-K commencing with the annual report for our fiscal year ending April 30, 2008.   We have incurred and, to the extent our working capital allows, will continue to incur significant increased costs in implementing and responding to these requirements. In particular, the rules governing the standards that must be met for management to assess its internal controls over financial reporting under Section 404 are complex, and require significant documentation, testing and possible remediation. Our process of reviewing, documenting and testing our internal controls over financial reporting may cause a significant strain on our management, information systems and other financial and human resources. We may have to invest in additional accounting and software systems. We may be required to hire additional personnel and to use outside legal, accounting and advisory services. In addition, we will incur additional fees from our auditors as they perform the additional services necessary for them to provide their attestation. If (because of a lack of financial resources or other reasons) we are unable to complete the work necessary to comply with the section 404 requirements, or we are unable to favorably assess the effectiveness of our internal control over financial reporting when we are required to, or if our independent auditors are unable to provide an unqualified attestation report on such assessment (if applicable for the fiscal year ending April 30, 2008), we may be required to change our internal control over financial reporting to remediate deficiencies. In addition, investors may lose confidence in the reliability of our financial statements causing our stock price to decline.

43




Item 2: Unregistered Sales of Equity Securities and Use of Proceeds

Clayton Dunning Capital Partners, Inc.

As consideration for entering into a financial advisory agreement on March 4, 2007 we granted Clayton Dunning Capital Partners, Inc. (“Clayton Dunning”) a warrant to purchase 100,000 shares of our common stock.   The following is the information required by Item 701 of Regulation S-K.

(a)                                  On March 5, 2007 we granted Clayton Dunning a warrant (which was simultaneously transferred to Roadrunner Capital Group) to purchase 100,000 shares of our common stock at $1.65 per share exercisable for two years.

(b)                                 There was no placement agent or underwriter for the transaction.

(c)                                  The warrant was issued in consideration for Clayton Dunning entering into a financial consulting agreement with us.

(d)                                 We relied on the exemption from registration provided by Sections 4(2) and 4(6) under the Securities Act of 1933 and Regulation D for the issuance of the common stock.   We did not engage in any public advertising or general solicitation in connection with this transaction.  The investor represented to us that it was an accredited investor and had access to all of our reports filed with the Securities and Exchange Commission, our press releases and other financial, business and corporate information.  Based on our investigation, we believe that the investor obtained all information regarding Isonics it requested, received answers to all questions it posed, and otherwise understood the risks of accepting our securities for investment purposes.

(e)                                  The warrant is exercisable or exchangeable into shares of common stock.

(f)                                    No cash proceeds were received.

CEOcast Inc.

On May 22, 2007 we entered into a consulting agreement with CEOcast Inc. (“CEOcast”), and as partial consideration for the investor relation services CEOcast will provide to us, we issued CEOcast 18,750 shares of our restricted common stock.   The following is the information required by Item 701 of Regulation S-K.

(a)                                  On May 22, 2007 we issued CEOcast 18,750 shares of our restricted common stock.

(b)                                 There was no placement agent or underwriter for the transaction.

(c)                                  The shares were issued in consideration for CEOcast entering into an agreement with us, and we received no cash therefore.

(d)                                 We relied on the exemption from registration provided by Sections 4(2) and 4(6) under the Securities Act of 1933 and Regulation D for the issuance of the common stock.   We did not engage in any public advertising or general solicitation in connection with this transaction.  The investor represented to us that it was an accredited investor had access to all of our reports filed with the Securities and Exchange Commission, our press releases and other financial, business and corporate information.  Based on our investigation, we believe that the investor obtained all information regarding Isonics it requested, received answers to all questions it posed, and otherwise understood the risks of accepting our securities for investment purposes.

(e)                                  The shares were common stock and, therefore, are not exercisable or exchangeable into shares of common stock.

(f)                                    No cash proceeds were received.

44




Sound Business Solutions, Inc.

On June 19, 2007, we entered into a consulting agreement with Sound Business Solutions, Inc, a corporation controlled by Joanna Lohkamp.  Ms. Lohkamp served as the Chief Operating Officer of our wholly owned subsidiary IVI  through September 7, 2007, and continues to be involved in the business in other capacities.   Pursuant to that agreement we granted Sound Business Solutions, Inc. options to purchase 200,000 shares of our common stock. The following is the information required by Item 701 of Regulation S-K.

(a)                                  On June 19, 2007, we granted Sound Business Solutions Inc. options to purchase 200,000 shares of our common stock pursuant to our 2005 Equity Plan (a portion not yet subject to a registration statement).  The options are exercisable at $1.45 and expire on June 18, 2011.  Options to acquire 66,667 shares vested immediately, options to acquire 66,667 shares vest on September 7, 2007, and 66,666 of the options vest on January 31, 2008.

(b)                                 There was no placement agent or underwriter for the transaction.

(c)                                  The options were granted in consideration for Sound Business Solutions Inc. entering into the consulting agreement by which it agreed to provide services to Isonics. We received no cash for the issuance of the options.

(d)                                 We relied on the exemption from registration provided by Sections 4(2) and 4(6) under the Securities Act of 1933 for the issuance of the stock options.   We did not engage in any public advertising or general solicitation in connection with this transaction, and we provided the investor with disclosure of all aspects of our business, including providing the investor with our reports filed with the Securities and Exchange Commission, our press releases, access to our auditors, and other financial, business, and corporate information. We believe that Ms. Lohkamp, the sole owner of Sound Business Solutions, is an accredited investor.  We believe that the investor obtained all information regarding Isonics it requested, received answers to all questions it (and its advisors) posed, and otherwise understood the risks of accepting our securities for investment purposes.

(e)                                  The stock options are exercisable to purchase shares of common stock as described above.

(f)                                    No proceeds were received.

Michael Caridi

On June 22, 2007, our wholly owned subsidiary PPSC entered into an employment agreement (the “Employment Agreement”) with Michael Caridi to serve as PPSC’s Senior Vice President.  Pursuant to the Employment Agreement, we granted Mr. Caridi options to purchase 150,000 shares of our common stock pursuant to our 2007 Restructuring Equity Plan, which plan is subject to shareholder approval.  The following is the information required by Item 701 of Regulation S-K.

(a)                                  On June 22, 2007, we granted Michael Caridi options to purchase 150,000 shares of our common stock.  The options are exercisable at $1.50 and expire on June 21, 2012.  The options are subject to the following vesting schedule:  (i) 50,000 options vested immediately; (ii) 25,000 shares vest six months from the date of the Employment Agreement;  (iii) 25,000 options vest nine months from the date of the Employment; and (iv)  50,000 shares vest upon achieving certain operating income levels for the fiscal year ending April 30, 2008.  Options shall only vest if Mr. Caridi is an employee of PPSC on each vesting date.

(b)                                 There was no placement agent or underwriter for the transaction.

(c)                                  The stock options were granted in consideration for Mr. Caridi entering into the employment agreement with our wholly-owned subsidiary,

45




PPSC.  We received no cash for the issuance of the options.

(d)                                 We relied on the exemption from registration provided by Section 4(2) under the Securities Act of 1933 for the issuance of the stock options.   We did not engage in any public advertising or general solicitation in connection with this transaction, and we provided the investor with disclosure of all aspects of our business, including providing the investor with our reports filed with the Securities and Exchange Commission, our press releases, access to our auditors, and other financial, business, and corporate information. We believe that the investor obtained all information regarding Isonics it requested, received answers to all questions he (and its advisors) posed, and otherwise understood the risks of accepting our securities for investment purposes.

(e)                                  The stock options are exercisable to purchase shares of common stock as described above.

(f)                                  No proceeds were received.

Item 4:  Submission of Matters to a Vote of Security Holders

None

Item 5: Other Information

We held our last annual meeting of shareholders on October 30, 2006, and a special meeting of our shareholders on January 2, 2007.  In the definitive proxy statement for our January 2, 2007 special meeting, we advised our shareholders that we expected to hold our next annual meeting of shareholders in October 2007, and that proposals from shareholders must be received by May 1, 2007 for consideration for inclusion in the proxy.  Due to a lack of working capital, we have decided to postpone our annual meeting of shareholders, but have not yet determined when we will hold the meeting or whether we will hold any meeting in our current fiscal year.  We have given consideration to holding the meeting in February 2008 or thereafter.  The Nasdaq Marketplace Rules require that our annual meeting of shareholders be held on or before the end of our current fiscal year (April 30, 2008).  As described above, it is likely that we will be delisted from Nasdaq before the end of our current fiscal year.  Although we do not yet know whether or when we will be holding our next shareholders’ meeting, we are requiring that proposals from our shareholders for consideration at the next meeting must be presented to us not later than October 1, 2007, and should be addressed to Corporate Secretary, Isonics Corporation, 5906 McIntyre Street, Golden, Co 80403.  After October 1, 2007, any shareholder proposal will be considered untimely.  If we extend the date of our shareholders’ meeting further, we will provide a new date for receipt of proposals.

Item 6: Exhibits

Exhibits.

3.1

 

Restated articles of incorporation (incorporated by reference from our Current Report on Form 8-K (File No. 001-12531), dated June 13, 2007 and filed on June 25, 2007, and incorporated herein by reference.

3.2

 

Restated bylaws (incorporated by reference from our Current Report on Form 8-K (File No. 001-12531), dated March 27, 2006, and filed on March 31, 2006, and incorporated herein by reference.

31.1

 

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act

31.2

 

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act

32.1

 

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350

32.2

 

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350

 

46




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Golden, County of Jefferson, State of Colorado, on the 14th day of September 2007.

Isonics Corporation

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

By

/s/ John Sakys

 

 

 

John Sakys

 

 

 

President, interim Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

By

/s/ Kenneth J. Deane

 

 

 

Kenneth J. Deane

 

 

 

Chief Accounting Officer and Chief Financial Officer

 

47